TW211568B - - Google Patents

Download PDF

Info

Publication number
TW211568B
TW211568B TW081110173A TW81110173A TW211568B TW 211568 B TW211568 B TW 211568B TW 081110173 A TW081110173 A TW 081110173A TW 81110173 A TW81110173 A TW 81110173A TW 211568 B TW211568 B TW 211568B
Authority
TW
Taiwan
Prior art keywords
compound
cyclopropyl
group
quinazoline
gas
Prior art date
Application number
TW081110173A
Other languages
Chinese (zh)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of TW211568B publication Critical patent/TW211568B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

A6 B6 五、發明説明(/) 本 發 明 關 於 具 有 治 療 活 性 的 眯 唑 喹 唑 啉 化 合 物 > 製 備 此 化 合 物 的 方 法 > 包 此 化 合 物 的 藥 學 組 成 物 * 及 以 其 治 療 的 方 法 0 此 新 穎 化 合 物 可 用 於 心 理 藥 物 的 製 備 > 如 治 療 中 揠 神 經 % 統 的 疾 病 » 例 如 抗 m 搦 劑 » 減 輕 焦 慮 , 催 眠 的 » 抗 精 神 病 的 > 抗 喔 吐 的 » 及 用 於 改 菩 哺 乳 動 物 大 腦 的 認 知 功 能 > 或 當 作 二 氣 雜 m 拮. 抗 劑 〇 在 脊 椎 的 中 握 神 經 % 統 的 持 定 位 置 上 存 在 有 結 合 1 1 4 — 和 1 » 5 — 二 氮 雜 萘 之 待 殊 親 和 力 是 習 知 的 ( S q U i Γ e S > R • F • 和 B Γ a e S t r U P 9 C • 1 η N a t U Γ e ( L 〇 η d 〇 η ) 2 6 6 ( 1 9 7 7 ) 7 3 (請先閱讀背面之;±意事項再塡寫本頁) 經濟部中央標準局員工消费合作社印製 2 - 7 3 4),這些位置叫作二氪雜萘受證。 現已發現許多的新穎眯唑氇唑啉化合物對於二氮雜萘 受Μ具有強親和力,因此其可用於心理藥物的裂備。 因此,本發明的一値目的卽是提供此新穎眯唑喹唑啉 化合物。A6 B6 V. Description of the invention (/) The present invention relates to a therapeutically active quinazoline compound > a method for preparing this compound > a pharmaceutical composition containing this compound * and a method for treating it 0 This novel compound is available Used in the preparation of psychological drugs > such as the treatment of neurological diseases »such as anti-m drugs» reduce anxiety, hypnosis »anti-psychotic> anti-vomiting» and used to improve the cognitive function of the mammalian brain > Or as an antagonist of diqizam. The antagonist 〇There is a combination of 1 1 4 — and 1 »5 — diazonaphthalene in the holding position of the central grip nerve of the spine. It is known (S q U i Γ e S > R • F • and B Γ ae S tr UP 9 C • 1 η N at U Γ e (L 〇η d 〇η) 2 6 6 (1 9 7 7) 7 3 (Please read the back side first; ± Issues before writing this page) Printed by the Employees Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs 2-7 3 4) These positions are known as dikrypton naphthalene. It has now been found that many novel oxazoline and porazoline compounds have strong affinity for diazonaphthalene, so it can be used for the preparation of psychotropic drugs. Therefore, an object of the present invention is to provide this novel quinazoline compound.

本發明化合物具有通式IThe compounds of the present invention have the general formula I

Q \fy 物 合 水 其 或 留 成 加 酸 的 受 接 可 上 物 藥 和 是 Q 中 其 本纸張尺及適用中國西家標準(CNS)甲4規格(210 X 297公货) 五、發明説明(Λ ) A6 B6 (諳先間讀背面之:玉意事項再塡寫本頁) 經濟部中央標準局員工消費合作社印製Q \ fy The hydrated or retained acid-acceptable overwhelming medicine and the original paper ruler in Q and the applicable Chinese Western Standard (CNS) A 4 specifications (210 X 297 public goods) V. Description of the invention (Λ) A6 B6 (Before you read the back: Jade Matters and then write this page) Printed by the Staff Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs

0-N0-N

0 — N0 — N

N 一0N a 0

R -C 其中 或C,c 直鏈 分別 氣基 0 0 R 1 或支 7 — 是c,c 非環 環胺 環或 子的 ,氧,硫 物,一非 R s 或-c N ; 是氫,直鍵或支鐽的C S烷基取代的C3 _7 6 院氧基— Cl 一 S — 鐽的C i s -烷基; 和R z分別是氫,C i 環烷基 1 _ s院基,未經取代的 環烷基,Ci _s烷氧基 烷基或三氟甲基;R8是R -C where either C, c straight chain is gas-based 0 0 R 1 or branch 7 — is c, c acyclic amine ring or daughter, oxygen, sulfur, a non-R s or -c N; is hydrogen , C3 _7 6 straight-chain or branched CS alkyl substituted C _7 6 oxy-Cl—S — C is -alkyl; and R z are hydrogen, C i cycloalkyl 1 _s Substituted cycloalkyl, Ci_s alkoxyalkyl or trifluoromethyl; R8 is

,二一C 烷 環烷基, 院氧基_ —6 一院基 縮銅, 基,在 .亞磺 環或環, Di-C alkane Cycloalkyl, Y-oxy-6 — Y-in-one, copper condensate, base, in .sulfinyl ring or ring

一個或多値C C 1 _ R 4 I ,三 烷基, 〇 -羥 ,R 5 氟甲基 C 2 _ 或R 2及 該環中条 醯基,磺 狀縮_ , _ s烷基 基烷基或 ,R 6分 .硝基, s烯烴基 基取代 C ! _ C 1 _ ,甲韹 R 2和 統中, 醯基或 這些環,C ! 苯基所 別是氫 胺基, ,C 2 院基, 基胺基 啶基, 基烷基 基,C C !— 氮原子形成 或多値 —院 的哌 6 m 6院 基一 一健 羰基 条統 _ 8 取代 ,羥 氡基 本纸張尺度適用中家作準(CNS)甲.1規丨各(210 X 297公坌) 選擇性的以C ,苯基取代, 或R 2和R 3One or more of CC 1 _ R 4 I, trialkyl, 〇-hydroxy, R 5 fluoromethyl C 2 _ or R 2 and the ring in the ring, sulfide-like _, _ s alkylalkyl Or, R 6 points. Nitro, s alkenyl substituted C! _ C 1 _, methyl R 2 and the system, the acetyl group or these rings, C! Phenyl group is a hydrogen amine group, C 2 Base, aminoaminopyridinyl, alkylalkyl, CC! — Nitrogen atom formation or multi-value—hospital 6 m. 6-homoyl—one health carbonyl system _ 8 substitution, hydroxyl radon basic paper size is suitable for home Standard (CNS) A.1 regulations (210 X 297 male) Selectively substituted with C, phenyl, or R 2 and R 3

C 烷 1 _ 6 —院氧 6院基或一其 一 4 — 6個原 碳原子可和m 所交換,或為其水合 的每一個可選擇性被 烷氧基一甲基,羥基 〇 基,C 1,B r , F ,直鏈或支鏈C i _ 一炔® 基,C 1 _ 6 A6C alkanes 1 _ 6 —Yuan oxygen 6 Yuan or one of the 4-6 original carbon atoms can be exchanged with m, or each of its hydration can be selectively alkoxy-methyl, hydroxy group, C 1, B r, F, linear or branched C i _ alkyne® group, C 1 _ 6 A6

五、發明説明(3 ) (:#先閱-、背面之;±-事項再塡寫本頁) 院氣基,Cl _ S院氣基_Cl _ 6院基或Ci _ S -院 氧基羰基; 其限制條件為當Q是Fifth, the description of the invention (3) (: #First read-, back of the page; ± -item and then write this page) Hospital air base, Cl _ S home air base_Cl _ 6 home base or Ci _ S-home oxygen Carbonyl; the restriction is that when Q is

時,R4 , R5 , R*5 , R7同時不能為氫; 其中R1 ’是H, Ct _s烷基或未經取代的C3 _7環 烷基;R2和R3分別是H, Ci _6 —烷氣基,C 3 一 7環烷基或Ci+s —烷基或NR2 R3形成一未經取代 的嗎啉或硫代嗎啉;且此式I化合物不是乙基6 —氛一 5 一嗎啉一眯唑〔1, 5 — a〕喹唑啉_3 —羧酸ΘΙ或6 — 氛一 3— (3 -環丙基一 1, 2, 4: -嗯哩—5 —基)一 5 -嗎啉一眯唑〔1 , 5 — a]唑唑啉。 本發明也關於製備上述化合物的方法,這些方法包括 經濟部中央標準局員工消費合作社印κ a )反應一式I I化合物和式I I I化合物, 本纸張尺Λ遇用中家作準(CNS)甲4规丨3· (210 X 297公坌) A6 B6 五、發明説明()When R4, R5, R * 5, R7 can not be hydrogen at the same time; where R1 'is H, Ct _s alkyl or unsubstituted C3 _7 cycloalkyl; R2 and R3 are H, Ci _ 6-alkyl gas group , C 3 -7 cycloalkyl or Ci + s —alkyl or NR 2 R 3 forms an unsubstituted morpholine or thiomorpholine; and the compound of formula I is not ethyl 6 —atmosphere 5 —morpholine squint Azole [1, 5-a] quinazoline _ 3 -carboxylic acid ΘΙ or 6-atmosphere 3-(3-cyclopropyl 1, 2, 4:-well 5-yl)-5-morpholine An azole azole [1, 5-a] oxazoline. The present invention also relates to methods for preparing the above-mentioned compounds. These methods include the printing of a compound of formula II and formula III by employees ’cooperatives of the Central Standards Bureau of the Ministry of Economic Affairs.丨 3 · (210 X 297 Gongbo) A6 B6 V. Description of the invention ()

7 R7 R

Y (II) 其中R2 , R 3 , R 4 , R 5 ,只6和卩7是如上述所定 義者,其中Y是一離去基, CN-CHz - Q (III) 其中Q是如上述所定義者,以形成一式I化合物,或 b)反應一具有通式IV化合犓之反應衍生物和一具有通 式V之化合物··Y (II) where R2, R3, R4, R5, only 6 and P7 are as defined above, where Y is a leaving group, CN-CHz-Q (III) where Q is as above Definer, to form a compound of formula I, or b) reacting a reactive derivative having the general formula IV compound and a compound having the general formula V ··

COOH (諳先閱汸背面之注意事項再塡寫本頁} (IV) 其中R2 , R 3 , R 4 , R 5 , R6和R7是如上述所定 義者, 經濟部中央標準局员工消費合作社印製COOH (keep reading the notes on the back of the board before writing this page) (IV) where R2, R3, R4, R5, R6 and R7 are as defined above, printed by the Staff Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs system

Rl - C ( = NOH) NHz (V) 其中R1是如上述所定義者,以形成一式I化合物,其中 Q是 本纸張尺度適用中S3家i?準(C!VS)甲4规烙(210 X 297公坌) 五、發明説明(Γ) 0-ΝRl-C (= NOH) NHz (V) where R1 is as defined above to form a compound of formula I, where Q is the S3 home standard (C! VS) A4 standard ( 210 X 297 gong) V. Description of the invention (Γ) 0-Ν

R 其中R1是如上述所定義者,或 c)反應一式VI化合物和一脱水劑,R where R1 is as defined above, or c) reacting a compound of formula VI with a dehydrating agent,

Α6 Β6 (VI) 其中R2 , R3 , R4 , R5 , R6和R7是如上述所定 義者,以形成一式I化合物,其中R2 , R 3 , R 4 , R 5 , Rs和R7是如上述所定義者,且其中Q是氡基,或 d)反應一式VI I化合物和NH2〇H,Α6 Β6 (VI) wherein R2, R3, R4, R5, R6 and R7 are as defined above to form a compound of formula I, wherein R2, R3, R4, R5, Rs and R7 are as defined above And where Q is a radon group, or d) reacts a compound of formula VI I with NH2〇H,

(V I I ) -------------------------^------’玎------^ (請先閲汸背面之注意事項再塡寫本頁) 經濟部中央標準局員工消費合作社印製 其中R2 , R3 , R4 , R5 , Rs和R7是如上述所定 義者,以形成一式VI I I化合物 本紙張尺茂適用中SK家作準(CNS)甲规格(2丨Ο X 297公殳)(VII) ------------------------- ^ ------ '玎 ------ ^ (Please read the back of 汸 first (Notes to be written on this page) Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs where R2, R3, R4, R5, Rs and R7 are as defined above to form a Formula VI II compound. SK Family Standard (CNS) Grade A (2 丨 Ο X 297 Gongshi)

A6 __B6_ 五、發明説明(4 )A6 __B6_ 5. Description of the invention (4)

OH (V I I I ) 其中R2 , R 3 , R 4 , R 5 , RS*R7是如上述所定 義者,且反應此式VI I I化合物和R1 — COOEt或 和(R1 CO) 2 0,其中R1是如上述所定義者,以形 成式I化合物,其中Q是 (請先閱讀背面之注意事項再塡寫本頁) 丨裝- N-0OH (VIII) where R2, R3, R4, R5, RS * R7 are as defined above, and the compound of formula VI II and R1 — COOEt or (R1 CO) 2 0, where R1 is as As defined above, to form the compound of formula I, where Q is (please read the precautions on the back before writing this page) 丨 Installed-N-0

R1 其中R1是如上述所定義者,或 e )水解式I化合物以形成式IX化合物 線 7R1 where R1 is as defined above, or e) hydrolyze the compound of formula I to form the compound of formula IX line 7

經濟部中央標準局員工消費合作社印製 其中Q, R 4 , R ^ . ^^^和尺7是如上述所定義者,且 反應式IX化合物和P0C 13以形成式X化合物 -10- 本紙張尺度適用中國國家桴準(CN’S)甲4現格(2ί0 X 297公:^ ) 經濟部中央標準局員工消費合作社印焚Printed by the Employee Consumer Cooperative of the Central Bureau of Standards of the Ministry of Economy where Q, R 4, R ^. ^^^ and ruler 7 are as defined above, and the compound of formula IX and P0C 13 are formed to form the compound of formula X-10- This paper The standard is applicable to the Chinese National Standard (CN'S) A 4 cash (2ί 0 X 297 g: ^) Printed by the Consumer Consumption Cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs

其和式X I化合物反應 N H R 2 R 3 (XI) 其中R2和R3具有如上述之定義者,以形成式I化合物 離去基Y可是任 專利第4 , 0 3 1 . ,例如,鹵素,烷硫 亞硝基基烷基胺基, R ) z ,其中R是較 ” )2 ,其中R ’和 和其所接觸的氮原子 院基,呢症基,或甲 鹼金颶條件下反應, 或鈉)鹼中烷氧化物 在一有機溶劑中進行 在反應筷件下是没有 的是無水非質子溶劑It reacts with a compound of formula XI NHR 2 R 3 (XI) where R2 and R3 have the above definitions to form a compound of formula I leaving group Y can be any patent No. 4, 0 3 1. For example, halogen, alkyl sulfide Nitrosoalkylamine group, R) z, where R is less than 2) 2, where R ′ reacts with the nitrogen atom, azyl group, or methylmethine under the conditions of its contact, or sodium ) The alkoxide in the base is carried out in an organic solvent. There is no under the reaction chopsticks. It is an anhydrous aprotic solvent.

何的合 0 7 9 基,例 烷氯基,氫碕基,一 OP ( 低级烷基或一 0 P 例如,描述於美國 9 , 4 2 0號中的 裝 適之群基, 或 4 . 3 5 如甲硫基,芳烷基硫基,N — R ”分別代表較低 一起代表一雜琿基 基對二 如在一 或氫化 .此有 反應性 .像二 氮己環基β 鹼中進行, 物是較佳的 機溶劑對於 的,待別是 甲基甲醛胺 11-He's combined 0 7 9 group, such as alkyl chloro group, hydrogen sulfonyl group, an OP (lower alkyl group or a 0 P For example, described in the United States No. 9, 4 2 0 in the appropriate group group, or 4.3 5 such as methylthio, aralkylthio, N-R "represents lower together represents a heteroethyl group to two as one or hydrogenation. This is reactive. Like in diazahexyl β base , The material is the preferred organic solvent, except for methylformaldehyde 11-

(Ο )( 级烷基或 ,像嗎啉 此反應較 在鹼金屬 。此反應 反匾物和 一無水溶 (D M F Ο ) (Ο N R J R 苯基,或 基,吡咯 诖的是在 (如,鉀 較佳的是 反應産犓 部i ,較佳 ),四氫 訂 線 本纸張尺度逯用中國因家1?準(CNS)甲4規_格(210 X 297公货) 上丄 '· ' i ο A6 B6 經濟部中央標準局員工消f合作社印製 五、發明説明(δ ) 呋 喃 ( T Η F ) » 或 其 類 似 物 〇 所 使 用 的 溫 度 可 B 疋 任 何 適 合 此 反 應 以 — 適 當 速 進 行 且 不 會 分 解 之 溫 度 > 通 常 是 從 一 4 0 至 约 室 溫 m 疋 待 別 適 用 的 〇 用 於 合 成 式 I 化 合 物 之 起 始 物 質 是 習 知 的 或 可 以 傳 統 方 式 由 商 業 化 物 質 裂 備 而 得 > 如 依 據 K a Γ m i η S k i e t a 1 • » J • E η V i Γ 〇 η • S G i • Η e a 1 t h t P a Γ t B i 1 9 8 3 Β 1 8 ( 4 — 5 ) 5 9 9 〇 本 發 明 化 合 物 的 藥 學 性 質 可 由 二 氮 雜 萘 受 jm 歴 取 代 放 射 性 m 示 的 f 1 U η i t Γ a Z e P a m 的 能 力 而 決 定 〇 本 發 明 化 合 物 的 取 代 的 能 力 可 經 由 決 定 E D 5 〇 的 值 而 決 定 〇 這 E D 5 〇 值 代 表 測 試 物 質 其 在 活 體 大 腦 中 引 起 3 Η — f 1 U η i t Γ a Z e P a m 與 二 氮 雜 萘 特 定 的 結 合 的 劑 量 ( m g / k g ) 降 低 至 控 制 值 的 5 0 % 〇 此 體 内 測 試 的 實 現 是 依 敘 述 於 美 國 專 利 第 4 * 7 7 4 I 2 4 5 號 的 方 法 〇 本 發 明 一 1¾ 化 合 物 的 m 試 結 果 列 於 下 列 表 I 〇 表 I 化 合 物 E D 5 〇 1 2 9 ο 〇 • 4 4 2 0 〇 • 2 9 2 4 0 5 -12 (請先閲汸背面之注意事頊再填寫本頁) .裝. 線. 本紙張尺度適用中國國家楞準(CNS>甲4蜆格(210 X 297公釐) 經濟部中央標準局員工消#合作社印製 A6 B6 五、發明説明(,) 本發明的化合物和一値傳統的佐藥,載體,或稀釋劑 ,且假使必須的話,以其藥學上可接受的酸加成塩的形式 ,可以其藥學組成物及單位劃量的形式,及以固醱的形式 施用,諸如:片錠或填充膠囊,或液體的形式,像溶液, 懸浮液,乳劑,佐藥,或是充滿這些物質的膠囊,所有的 都是口服,或適於直腸治療的塞藥的形式;或非經腸(包 括皮下的)使用的無菌注射溶液的形式。此藥學的成份與 其單位劑量的形成可包含傳統比例的傳統成份,具有或不 具有附加的活性化合物或成份,且此單位劑量形式可包含 任何合適的有效量的中握神經条统煩悶減輕的活性成分, 其是每日打算使用的劑量範圍。片錠可,毎片,包含0. l-100mg的活性的成分,持別是1. 0 — 50mg 是本發明合適的單位劑量形式的代表。 本發明化合物可用作醫藥製備物之配方,例如供包活 人類的哺乳動物口服和非經腸用藥,依照傳統G a 1 e η氏醫 藥方法。 傳統賦形劑為發藥可接受有機或無機載體物質,適合 非绥腸或口服使用而不與活性化合物起有害反應。 此載體例子為水,塩水溶液,乙醇,聚乙二醇,聚羥 基乙烷氧基化Μ麻油,明膠,乳酸,直鍵澱粉,硬脂酸鎂 ,滑石粉,硅酸,脂肪酸單甘油酯和脂肪酸雙甘油酯,季 戊四醇脂肪酸酯,羥基甲基纖維素和聚乙烯吡咯烷酮。 視需要將醫藥製備物以輔肋劑予以消毒和混合,輔肋 -13- ------------------------裝——-----玎------線 f諳先閱冶背面之注念事項再塡寫本頁) 本紙張尺度適用中西因家標準(CNS>甲Ο見格(210 X 297公* > 81.9.20,000· 缦濟部t央搮準局員工消费合作社印製 A6 B6 五、發明説明(Ισ ) 剤,例如潤滑劑,穩定劑,潤濕劑,乳化雨,影鬱滲透壓 之塩,缓衝液和/或著色物質等,不會與活性化合物反睡 而破壞之。 非經腸暱用,尤其適合者為可注射溶液或懸浮液,較 佳者為活性化合拗溶於聚羥基化Μ麻油所形成水溶液。 安瓿為方便之單位劑量.形式。 在口服應用方面,待別合適者為錠片、糖衣九或有滑 石和/或碩水化合物載饈或接合剤等類似物之膠囊,載醱 較佳為乳糖和/或毅類源粉和/或馬鈐薯澱粉。當使用甜 化賦形劑時,便可採用搪漿,酏剤或類似物。大髏而言, 就更廣泛範圍本發明化合物配成單位剤置形式,内含〇. 0 5至1 0 0毫克於單位劑量醫藥可接受載腥。 典型錠片可以傳統製錠技術完成,其包括: 活性化合物 1. 〇毫克 乳 糖 67.3毫克 ph.Eur(Ο) (grade alkyl or, like morpholine, this reaction is more in alkali metals. This reaction is anti-plaque and a water-insoluble (DMF Ο) (Ο NRJR phenyl, or phenyl, pyrrole is in (eg, potassium The better one is the reaction production part i, which is better). The paper size of the tetrahydro-stranded book is the Chinese In-House 1? Standard (CNS) A 4 regulation _ grid (210 X 297 public goods) 上 丄 '·' i ο A6 B6 Printed by the Employees ’Cooperative of the Central Bureau of Standards of the Ministry of Economy V. Description of invention (δ) Furan (T Η F)» or its analogue 〇 The temperature used can be any suitable for this reaction-proceed at an appropriate speed And the temperature that does not decompose > is usually from a 40 to about room temperature m. It will be suitable for other applications. The starting materials used in the synthesis of compounds of formula I are known or can be prepared from commercial materials in a conventional manner. Get> As per Ka Γ mi η S kieta 1 • »J • E η V i Γ 〇η • SG i • Η ea 1 tht P a Γ t B i 1 9 8 3 Β 1 8 (4 — 5) 5 9 9 〇 copies The pharmacological properties of the compound can be determined by the ability of the diazonaphthalene to replace the f 1 U η it Γ a Z e P am indicated by the radioactivity m. The ability of the compounds of the invention to be substituted can be determined by determining the value of ED 5 〇 It is determined that the ED 5 〇 value represents the dose of the test substance which causes a specific combination of 3 Η — f 1 U η it Γ a Z e P am and diazonaphthalene (mg / kg) in the living brain to a reduced value 50% 〇 This in vivo test was implemented according to the method described in US Patent No. 4 * 7 7 4 I 2 4 5. The results of the test of the compound of the present invention are listed in the following Table I. Table I Compound ED 5 〇1 2 9 ο 〇 • 4 4 2 0 〇 • 2 9 2 4 0 5 -12 (please read the precautions on the back of 汸 before filling out this page). Install. Line. This paper size is applicable to China National Leng Zhun (CNS> A4 clam (210 X 297 mm) A6 B6 printed by the Ministry of Economic Affairs Central Standards Bureau staff consumer #cooperative society V. Description of the invention (,) The compound of the present invention and a traditional adjuvant, carrier , Or diluent, and if necessary, in the form of its pharmaceutically acceptable acid additions, can be administered in the form of its pharmaceutical composition and unit amount, and in the form of solid sulfide, such as tablets or fillings Capsules, or liquid forms, like solutions, suspensions, emulsions, adjuvants, or capsules filled with these substances, all taken orally, or in the form of plugs suitable for rectal treatment; or parenteral (including subcutaneous The form of sterile injectable solution. The formation of this pharmaceutical ingredient and its unit dose may include traditional ingredients in traditional proportions, with or without additional active compounds or ingredients, and this unit dosage form may contain any suitable effective amount of activity to reduce boredom in the middle-grip nerve system Ingredients, which are the daily intended dosage range. Tablets can be, every tablet, containing 0.1-100 mg of active ingredient, with a range of 1.0-50 mg is a representative of a suitable unit dosage form of the present invention. The compounds of the present invention can be used in the formulation of pharmaceutical preparations, for example, for oral and parenteral administration to mammals entrapped in humans, in accordance with traditional Ga 1 e η's medical methods. Traditional excipients are organic or inorganic carrier substances that are acceptable for hair release and are suitable for non-suiwan or oral use without adverse reactions with the active compound. Examples of such carriers are water, aqueous solution of saline, ethanol, polyethylene glycol, polyhydroxyethoxylated sesame oil, gelatin, lactic acid, amylose starch, magnesium stearate, talc, silicic acid, fatty acid monoglyceride and Fatty acid diglyceride, pentaerythritol fatty acid ester, hydroxymethyl cellulose and polyvinylpyrrolidone. Disinfect and mix the pharmaceutical preparations with supplementary ribs if necessary, supplementary ribs-13- ------------------------ installed ------- -玎 ------ Line f is familiar with the notes on the back and then write this page) This paper scale is applicable to the Chinese and Western standards (CNS > A Ο 見 格 (210 X 297 公 *> 81.9 .20,000 · Printed A6 B6 by the Employee Consumer Cooperative of the Ministry of Manchurian Economy. V. Description of invention (Ισ), such as lubricants, stabilizers, wetting agents, emulsified rain, shadow osmotic pressure, buffer And / or coloring substances, etc., will not be destroyed by sleeping with the active compound. Non-enteric use, especially suitable for injectable solutions or suspensions, preferably active compound dissolved in polyhydroxylated sesame oil Form an aqueous solution. Ampoules are convenient unit dosage forms. For oral use, tablets, sugar-coated tablets or capsules with talc and / or hydrotalcite-containing compounds or conjugates, etc. It is preferably lactose and / or Yi-type source powder and / or yam potato starch. When sweetening excipients are used, slush, syrup or the like can be used. A wider range of the compounds of the present invention are formulated in unit placement form, containing 0.05 to 100 mg in a unit dose pharmaceutically acceptable to contain fish. Typical tablets can be completed by traditional tablet manufacturing techniques, which include: active compound 1. 〇mg lactose 67.3mg ph.Eur

Avicel 31.4 毫克Avicel 31.4 mg

Aiberlite IR P 38 1.0 毫克 硬脂酸il 0.25毫克 ph.Eur 由於本發明化合掬對二氪雜萘受證具備高度親和性. 在治療中櫃神經条统疾病或不健全方面相當有效,給予有 效剤量能達到減輕,改菩或消除病情者。本發明化合物之 重要中樞神經条統活性包括抗痙攀、減輕焦慮,安眠藥、 抗精神病的,和抗嘔吐的活性,以低毒性改菩哺乳動物大 -14- 本纸張A及適用中因國家標準(CNS)甲4規格(210 X 297公;Ϊ > ------------------------装—.——.玎------線. (請先閲it背面之注意事項再填寫本頁) 丄丄d A6 B6 五、發明説明(丨丨) (琦先閱:»'背面之注t事項再塡寫本頁) 腦認知的功能,且其存在有最有效的醫療指引。本發明化 合物據此可給予用藥,對象為活體動物或人體,用來治療 、減輕、改善或消除病徵以及中櫃神經条统和所諝二氮雜 萘受證,其需要此心理醫藥治療,例如,待別是痙孿、失 眠、焦慮不安,精神病,喔吐,疑呆症,及/或當作二氪 雜萘受體拮抗劑,視需要以.其醫藥可接受酸加成塩形式( 如溴化氫,氛化氫,酒石酸鹽,或硫酸塩,於製備自常見 或傳統方式之任何事件中,如將溶液中游離鹼與酸一起蒸 乾),通常一起.與醫藥上可接受載體或稀釋劑並存,待別 和較佳以一其醫藥組成物形式存在,藉口服,經直腸或非 經腸(包括皮下方式.)途徑,以減輕心理醫藥中樞神經条 統疾病之有效劑量,例如,一抗痙孿,減輕焦慮,催眠及 /或抗精神病的劑量,有效減輕中樞神經条統疾病之有效 割量乃由於對二氮雜萘受體之親和性。合適劑量為毎天1‘ 一 200毫克,毎天1-100毫克,待別為每天1 一 3 〇毫克,照往例依正確用藥方式,用藥形式,用藥針對症 狀治療對象,對象體重,以及醫生或獸醫的偏好和經驗% 定 經濟部中央標準局員工消費合作社印製 的 性 例 實 3 進 做 例 施 實 述 下 以 將 明 發 本 制 限 非 是 其 旦 /1 述 詳 步 3 啉 瞟 - 5 4 唑 , 眯 2 _ , 基 1 甲 - 氟 基三 丙 -環 6 } 啉 基唑 | 喹 5 ] I a ί戊 I 氮 5 二 , 氧 1 本紙張尺及適用tHK家丨準(CNS)甲4現格(2L0 X 297公;^ ) ~^E^2ll0t3 Λ6 B6 五、發明説明(1之) 化合物1 ) 經濟部中央標準局具工消費合作社印製 於 —* m 拌 的 2 一 氯 一 4 一 嗎 啉 — 5 一 三 氟 甲 基 — 唑 啉 ( 6 〇 0 m 8 > 1 9 m m 〇 1 ) 和 3 — 環 丙 基 — 5 — 異 氰 基 甲 基 — 1 > 2 » 4 — 氧 二 氮 S ( 4 4 0 m g t 2 • 9 m m 〇 1 ) 溶 於 無 水 D Μ F ( 1 5 m 1 ) 的 溶 液 中 > 在 氮 氣 氣 氛 下 及 5 — 1 0 TC 的. 溫 度 範 圍 内 加 入 固 am 歴 叔 — 丁 氧 化 鉀 ( 3 3 〇 m g » 2 - 9 m m 〇 1 ) t 於 5 一 1 0 V 的 溫 度 下 繼 缠 m 拌 此 混 合 物 〇 • 5 小 時 > 及 以 水 研 磨 ( 2 〇 m 1 ) 〇 過 濾 出 结 晶 物 1 且 以 水 ( 1 〇 m 1 ) 和 醋 酸 乙 酯 洗 灌 〇 最 後 純 化 是 將 此 结 晶 物 m 拌 於 丙 酮 中 ( 1 〇 m 1 ) > 可 得 3 3 〇 m 8 的 標 題 化 合 物 » m • P • 1 9 ~7 — 1 9 9 v 〇 1 Η η m r 3 ( C D C 1 3 ) : δ 8 • 4 ( S » 1 Η t 眯 唑 — ) 9 8 • 2 — 7 9 ( m » 3 Η » 苯 並 — ) 4 • 〇 — 3 • 2 ( m t 8 Η » 嗎 啉 基 一 ) * 2 • 2 ( m r 1 Η » C Η ) , 1 畢 3 — 1 * 0 ( m > 4 Η t C Η Z ) 〇 實 例 2 — ( 3 — 環 丙 基 — 1 » 〇 » 4 — 氧 二 氮 茂 一 5 — 基 \ — 6 — 甲 基 — 5 — m 啉 — 眯 唑 r 1 > 5 — a ] 喹 唑 啉 ( 化 合 物 2 ) 一 混 合 物 > 包 括 2 — 氨 — 5 — 甲 基 — 4 — 嗎 啉 基 — 痤 唑 啉 ( 1 • 6 8 g * 6 • 4 m m 〇 1 ) 和 3 — 環 丙 基 一 5 — 異 m 基 甲 基 — 1 » 2 * 4 — 氣 二 氮 ( 1 9 8 ) 溶 解 -16- ,(-先閱‘;:1'.背面之;±-?項再塡寫本頁) 裝‘ 訂. -線 本紙張尺Λ適用中國S家浮準(CNS)甲4規格(210 X 297公货) 211〇βύ 經濟部中央標準局員工消費合作社印製 五、發明説明(丨s ) 於 1 5 m 1 的 無 水 二 甲 基 甲 醯 胺 中 > 將 其 冷 却 至 0 V > 及 在 5 分 鐘 内 慢 慢 的 加 入 叔 — 丁 氣 化 鉀 ( 1 • 4 g > 1 2 5 m m 〇 1 ) » 溫 度 保 持 在 1 0 〇 在 室 溫 下 m 拌 此 混 合 物 兩 小 時 i 然 後 却 至 0 °C 〇 過 遽 收 集 結 晶 Zrh OL 澱 物 f 在 過 滴 器 中 以 醋 酸 乙 酯 和 水 洗 iSW m » 乾 燥 後 可 得 標 題 化 合 物 其 為 淡 黃 色 的 結 晶 物 » m P. • 1 6 2 — 2 6 6 > 産 1 • 2 9 g 〇 1 Η η m Γ δ ( C D C 1 3 ) δ : 8 • 3 〇 ( S > 1 Η > 眯 唑 — ) 7 • 8 5 — 7 • 3 5 ( m 3 Η » 苯 並 一 ) > 4 〇 5 — 3 8 ( m > 4 Η » Ν — C Η 2 ) » 3 • 7 5 — 3 . 3 〇 ( m t 4 H * 0 — C Η 2 ) > 2 3 8 ( S » 3 Η » C Η 3 ) y 2 * 3 0 — 2 • 1 2 ( m » 1 Η t C Η ) y 1 3 — 1 • 0 ( m > 4 Η > C Η Ζ ) 〇 以 類 似 的 方 法 製 備 下 列 化 合 物 6 — 溴 — 3 — ( 3 — 環 丙 基 — 1 , 2 > 4 — 氧 二 m 茂 — 5 — 基 ) — 5 一 嗎 啉 — 眯 唑 C 1 ) 5 — a ) 喹 唑 啉 ( 化 合 物 3 ) V m • P • 2 7 5 — 2 7 7 °C » 由 2 — 氯 — 5 — 溴 — 4 - 嗎 琳 基 — 喹 唑 啉 和 〇 一 環 丙 基 — 5 — 異 氡 基 甲 基 — 1 > 2 » 4 — 氣 二 氮 茂 製 備 而 得 ; 叔 — 丁 基 6 一 甲 基 — 5 — 硫 代 嗎 啉 基 — 眯 唑 C 1 » 5 — a Ί J 唆 唑 啉 — 3 — 羧 酸 酯 ( 化 合 物 4 ) m Ρ • 1 6 4 — 1 6 6 » 由 2 — 氛 — 5 一 溴 — 4 — 硫 代 嗎 啉 基 — 喹 唑 啉 和 叔 —— 丁 基 異 氛 基 乙 酸 酯 反 應 製 備 而 得 ; -17- (-"閱-、背面之:;i-fJfi再塡寫本頁) 本纸張尺度適用中國K家桴準(CiVS)甲4規格(210 X 297公釐) A6 B6 2li〇6d 五、發明説明(丨红) 6 — 溴 — 3 —一 ( 3 一 環 丙 基 — 基 ) — 5 一 ( N — ( 2 ) 基 胺 基 ) — 眯 唑 Γ 1 1 5 一 • P • 1 7 〇 — 1 7 1 X: > — ( 2 t 2 — 二 甲 氧 基 乙 基 3 — 環 丙 基 一 5 — 異 氰 基 甲. 備 而 得 1 3 — ( 5 — 環 丙 基 — 1 » 2 6 — 甲 基 — 5 — 硫 代 嗎 啉 — 化 合 物 6 ) m • P • 2 〇 — 甲 基 — 4 — 硫 代 嗎 啉 基 — % 基 甲 基 — 1 » 2 * 4 — 氧 6 — 漠 — 3 — ( 3 — 環 丙 基 — 基 ) — 5 一 ( N — 乙 氧 基 眯 唑 C 1 > 5 — a 喹 唑 啉 9 — 1 9 1 t: 9 由 2 — 氮 — 基 甲 基 — N — 甲 基 胺 基 ) — 氰 基 甲 基 — 1 ♦ 2 > 4 — 氧 7 — 氛 — 3 一 ( 3 一 環 丙 基 — 基 ) — 5 — ( N » N — 雙 — 味 唑 r 1 1 » 5 — a ] 喹 唑 1 2 — 2 1 5 V » 由 2 t 6 — 甲 氧 基 乙 基 ) 胺 基 ) 一 m ------------------------裝------,玎------^ (沐先閲汸背面之;±念事嘈再填寫表頁) 經濟部中央標準居員工消費合作社印焚 -1, 2, 4 -氧二氮 S-5 2 —二甲氣基乙基)一 N —甲 a〕喹唑啉(化合物5) , mAiberlite IR P 38 1.0 mg stearic acid il 0.25 mg ph.Eur Because the compound of the present invention has a high affinity for dikryptonnaphthalene. It is quite effective in the treatment of neurological disorders or insufficiency in the middle. It is effective. The amount can be reduced, to change the bodhisattva or eliminate the disease. The important central nervous system activities of the compounds of the present invention include antispasmodic, anxiolytic, hypnotic, antipsychotic, and antivomiting activities, which are modified with low toxicity to mammals. Standard (CNS) A 4 specifications (210 X 297 g; Ϊ > ------------------------ installed —.——. 玎 --- --- Line. (Please read the precautions on the back of it before filling in this page) 丄 丄 d A6 B6 V. Description of the invention (丨 丨) (Qi first read: »'Notes on the back of the page and then write this page) The function of brain cognition, and its existence has the most effective medical guidance. The compound of the present invention can be administered according to this, the object is a living animal or human body, used to treat, alleviate, improve or eliminate the symptoms and the neurological system Diazonaphthalene is certified and needs this psycho-medical treatment, for example, to treat spasticity, insomnia, anxiety, psychosis, vomiting, suspense, and / or as a kryptonine receptor antagonist, In the form of pharmaceutically acceptable acid addition salts (such as hydrogen bromide, hydrogenated hydrogen, tartrate, or sulfate sulfate), if necessary, prepared from common or traditional methods In any event, such as evaporating the free base and acid together in the solution), usually together. It coexists with a pharmaceutically acceptable carrier or diluent, and is preferably present in the form of a pharmaceutical composition. Rectal or parenteral (including subcutaneous) methods to reduce the effective dose of psychopharmacological central nervous system diseases, such as primary antispasmodic, anxiety, hypnotic and / or antipsychotic doses, effectively reduce central nervous system The effective cut of traditional diseases is due to the affinity for the diazonaphthalene receptor. The appropriate dose is 1 'to 200 mg per day, 1 to 100 mg per day, and 1 to 30 mg per day, as usual According to the correct medication method, medication form, medication for symptomatic treatment target, target weight, and the preference and experience of the doctor or veterinarian% The sex example printed by the employee consumer cooperative of the Central Bureau of Standards of the Ministry of Economic Affairs 3 The cost limit is not the same as described in the first step. 3 Pyridin-5 4 azole, squint 2 _, yl 1 methyl-fluorotripropyl-cyclo 6} linyl azole | quine 5] I a ίpent I nitrogen 5 two , Oxygen 1 paper ruler and applicable tHK home standard (CNS) A4 cash (2L0 X 297 g; ^) ~ ^ E ^ 2ll0t3 Λ6 B6 V. Description of invention (1) Compound 1) Central Bureau of Standards, Ministry of Economic Affairs Printed by Gugong Cooperative Cooperative in 2 * -chloromethylene 4-monomorpholine-5 monotrifluoromethyl-oxazoline (6 〇0 m 8 > 1 9 mm 〇1) and 3-cyclopropyl — 5 — Isocyanomethyl — 1 > 2 »4 — Oxydiazepine S (4 4 0 mgt 2 • 9 mm 〇1) dissolved in a solution of anhydrous D MF (1 5 m 1) > in Under a nitrogen atmosphere and 5-10 TC. Add solid ammonium-butyrate (3 3 〇mg »2-9 mm 〇1) t within the temperature range and mix at a temperature of 5-10 V This mixture was 〇 • 5 hours> and ground with water (2 〇m 1) 〇 filtered out crystal 1 and washed with water (1 〇m 1) and ethyl acetate was poured into the final purification is to mix this crystal m (1 〇m 1) in acetone> 3 3 〇m 8 of the title compound »m • P • 1 9 ~ 7 — 1 9 9 v 〇1 Η η mr 3 (CDC 1 3): δ 8 • 4 (S »1 Η t 眯 azole—) 9 8 • 2 — 7 9 (m» 3 Η »benzo—) 4 • 〇— 3 • 2 (mt 8 Η »morpholinyl one) * 2 • 2 (mr 1 Η» C Η), 1 bis 3 — 1 * 0 (m > 4 Η t C Η Z) 〇Example 2 — (3 — Cyclopropyl — 1 »〇» 4 — oxydiazepine 5 — yl \ — 6 — methyl — 5 — m porphyrin — benzozole r 1 > 5 — a] Quinazoline (Compound 2) A mixture> including 2 — ammonia — 5 — methyl — 4 — morpholinyl — oxazoline (1 • 6 8 g * 6 • 4 mm 〇1) and 3 — cyclopropyl- 5 — iso-m-methyl Base — 1 »2 * 4 — Gas dinitrogen (1 9 8) Dissolve -16-, (-read first ';: 1'. The back of it; ±-? Item and then write this page) Binding 'Order.-Line This paper ruler Λ is applicable to China S Jiafuzhun (CNS) Grade 4 (210 X 297 public goods) 211〇βύ Printed by the Employees Consumer Cooperative of the Central Standards Bureau of the Ministry of Economic Affairs Ming (丨 s) in 15 m 1 of anhydrous dimethylformamide > Cool it to 0 V > and slowly add tert-butyrate gas (1 • 4 g > 5 minutes) ; 1 2 5 mm 〇1) »The temperature is kept at 1 0 〇 Mix the mixture at room temperature for two hours i and then to 0 ° C 〇 Collect the crystallized Zrh OL precipitate f in the dropper with ethyl acetate Esters and washed with water iSW m »After drying, the title compound is obtained as pale yellow crystals» m P. • 1 6 2 — 2 6 6 > yield 1 • 2 9 g 〇1 Η η m Γ δ (CDC 1 3 ) δ: 8 • 3 〇 (S > 1 Η > 眯 azole—) 7 • 8 5 — 7 • 3 5 (m 3 Η »benzo-I) > 4 〇5 — 3 8 (m > 4 Η »Ν — C Η 2)» 3 • 7 5 — 3. 3 〇 (mt 4 H * 0 — C Η 2) > 2 3 8 (S »3 Η» C Η 3) y 2 * 3 0 — 2 • 1 2 (m »1 Η t C Η) y 1 3 — 1 • 0 (m > 4 Η > C Η ζ) 〇 Prepared in a similar way Column compound 6 — bromo — 3 — (3 — cyclopropyl — 1, 2 > 4 — oxodimethane-5 — yl) — 5 monomorpholine — quinazoline C 1) 5 — a) quinazoline ( Compound 3) V m • P • 2 7 5 — 2 7 7 ° C »From 2 — Chlorine — 5 — Bromine — 4 — Morinyl — Quinazoline and O—Cyclopropyl — 5 — Isoradyl methyl — 1 > 2 »4 — prepared by gas diazoxide; tert-Butyl 6 monomethyl— 5 — thiomorpholinyl — zonazo C 1» 5 — a Ί J oxazoline — 3 — carboxyl Ester (Compound 4) m Ρ • 1 6 4 — 1 6 6 »Reaction from 2 — atmosphere — 5 monobromo — 4 — thiomorpholinyl — quinazoline and tert-butyl isocyanoacetate Prepared; -17- (-" read-, back:; i-fJfi and then write this page) This paper scale is suitable for China K Jiazheng (CiVS) A 4 specifications (210 X 297 mm) A6 B6 2li〇6d Fifth, the description of the invention (丨 red) 6-bromo-3-one (3-cyclopropyl-yl)-5 (N — (2) amino group) — benzozole Γ 1 1 5-P • 1 7 〇— 1 7 1 X: > — (2 t 2 — dimethoxyethyl 3 — cyclopropyl one 5 — Isocyanomethyl. Prepared 1 3 — (5 — Cyclopropyl — 1 »2 6 — Methyl — 5 — Thiomorpholine — Compound 6) m • P • 2 〇— Methyl — 4 — Thiomorpholinyl —% ylmethyl — 1 »2 * 4 — Oxygen 6 — Mo — 3 — (3 — Cyclopropyl — yl) — 5 — (N — Ethoxyphenazole C 1> 5 — a Quinazoline 9 — 1 9 1 t: 9 consists of 2 — nitrogen — ylmethyl — N — methylamino) — cyanomethyl — 1 ♦ 2 > 4 — oxygen 7 — atmosphere — 3 one (3 Cyclopropyl-yl) — 5 — (N »N — bis-acidazole r 1 1» 5 — a] Quinazol 1 2 — 2 1 5 V »from 2 t 6 — methoxyethyl) amine group) One m ------------------------ installed ------, 玎 ------ ^ (mu first read the back of 汸; ± Please fill in the form and page again) Printed and burned by the Ministry of Economic Affairs Central Standard Residence Staff Consumer Cooperative -1, 2, 4-oxydiazepine S-5 2-dimethylaminoethyl) N-methyl a] quinazoline (compound 5), m

由 2 — 氱一 5_溴一4 - ( N )一 N -甲基胺基)嗤唑啉和 基一 1, 2, 4 —氧二氮S製 ,4 一氣二氮茂_3_基)_ 眯唑〔1, 5 - a〕《唑啉( 5 — 206Ό,由 2 — 氣一5 喹唑啉和5—環丙基一3_異 二氮S製備而得; 一 1, 2, 4 — 氣二氣茂一 5 羰基甲基一 Ν —甲基胺基)一 (化合物 7) , m. ρ· 18 5 —溴一 4 — (N —乙氣基羰 喹唑啉和3—環丙基一5—異 二氮茂裂備而得; 一 1, 2, 4 — 氣二氮茂-5 (2 —甲氧基乙基)一胺基) 琳(化合物8) , m. p. 2 一二氣一 4 ( N , N — 雙(2 唑啉和3 —環丙基一 5 —異氡 18- 本紙張尺度通用中®西家標準(CNS>甲4规格(210 X 297公» ) 81.9.20,000 經濟部中央標準局。«工消費合作钍印5< f · A6 ,B6 五、發明説明(I r) 基甲基一 1, 2, 4 —氣二氮茂製備而得; 7 —氛一3 — (3 —環丙基一 1, 2, 4 —氣二氮茂一 5 一基)一5 - ( N - (1, 3 — 二噁烷一 2 — 基)一甲基 —N —甲基胺基)一眯唑〔1, 5 — sl]喹唑啉(化合物 9) ,m. p. 223 — 226C,由 2, 6 -二氨一4 -(N - (1, 3 -二噁烷一2 -基)甲基一N -甲基胺 基)一喹唑啉和3_環丙基一 5 —異氡基甲基一 1, 2, 4 一氣二氮茂製備而得; 3 - (3 —環丙基一 1, 2,4 一 氣二氮 S — 5 —基)— 7 —氣—5 —嗎啉一眯唑C1, 5 — a〕嗤唑啉(化合物 1〇),m. p. 243-2451,由 2 —氣一6 —氟 —4 _嗎啉基—喹唑啉和3 —環丙基一 5 —異m基甲基一 1, 2, 4 -氧二氮S製備而得; 乙基7 —氟一5 —嗎啉基一眯唑〔1, 5 — a〕喹唑啉一 3 — 羧酸酯(化合物 11) , m. p. 238 — 239t ,由2 —氛一 6 —氟一 4 —嗎啉基一喹唑啉和乙基異氰酸 酯製備而得; 異丙基7 -氯一 5 — ( N - (1, 3 —二噁烷-2 —基) 甲基一 N —甲基胺基)眯唑〔1, 5 — a〕喹唑啉一 3 — 羧酸酯(化合物12) , m . p . 1 3 5 - 1 3 7 TC ,由 2,6—二氣一4 一 ( N — (1, 3 — 二噪院 _2_ 基) -甲基- N —甲基胺基)喹唑碑和異丙基異氰基乙酸酯製 備而得; -1 9- 本纸掁又度適則中國西家標準(CNS) V 〇見格(210 X 297公货) 81.9.20.000 ------------------------裝------.ΤΓ------.^. (請先閲汸背面之注念事項再塡寫本頁) 0 0 經濟部中央標準局R工消Φ合作钍印5代 Α6 Β6 五、發明説明(ις ) 9 一氛一 3 — (3 —環丙基一 1, 2, 4 —氣二氮茂一 5 一基)一 5 -嗎啉一眯唑〔1, 5 - a〕噇唑啉(化合物 13) , m . p . 121-124C,由 2, 8 — 二氛一 4 一噶啉基_喹唑啉和3_環丙基一 5 -異氰基甲基一 1 ,2, 4_氧二MS裂備而得; 9 -氣一 3 - (3 -環丙基-1, 2, 4 -氣二氮茂-5 一基)一 5 - (4 -甲基一 1 一對二氮己環基)一眯唑〔 1, 5 — a]喹睡啉(化合物 14) , m . p . 1 9 9- 20 It:,由 2, 8 -二氨一4 - (4 -甲基一 1 一對二 氮己環基)一喹唑啉和3_環丙基一 5 —異氛基甲基一 1 ,2, 4 —氣二氮S製備而得; 6, 9— 二氛一 3 — (3 —環丙基一 1, 2, 4 —氧二氣 5 — 5 —基)一 5 —嗎啉一眯唑〔1, 5 — a〕喹唑啉( 化合物 15) , m . p . 1 8 4 - 1 8 6 °C ,由 2, 5, 8 —三氛_ 4 一瞟啉基一喹唑啉和3 —環丙基一 5 —異氛 基甲基—1, 2, 4 —氧二氮S製備而得; 7 —氣一 3 — (5 —甲氣基甲基一 1, 2 , 4 一氣二氮茂 一 3 —基)一5 - (N —乙基-N —甲基胺基)眯唑〔1 ,5 - a〕喹哩琳(化合樹 16) P. 169—1 7 2 t:,由2, 6 —二氨一4 - (N —甲基一N —乙基胺 基)一喹唑啉和3 —異氰基甲基一 5 —甲氧基甲基一 1 , 2, 4 —氧二氮茂製備而得; 3 — (3 —環丙基一 1, 2, 4 -氣二氮茂一 5 -基)一 -20- 本纸張尺度適用中西國家標準(CNS)甲4说格(210 X 297公货) 81.9.20.000 ------------------------裝------,玎------^ (諳先閲-背面之注念事嘈再填寫本頁)Made from 2-—5_bromo-4— (N) —N-methylamino) oxazoline and 1,2,4-oxydiazepine S, 4-gas diazepine_3_yl) _ 眯 azole [1, 5-a] oxazoline (5-206Ό, prepared from 2-gas-5quinazoline and 5-cyclopropyl-3-isodiazepine S; 1, 2, 4 — Gas dioxo-5 carbonylmethyl-N-methylamino) (compound 7), m. Ρ · 18 5-bromo-4- (N-ethoxycarbonylquinazoline and 3-cyclopropyl A 5-isodiazepine is prepared by cracking; a 1, 2, 4- gas diazino-5 (2-methoxyethyl) monoamine) Lin (compound 8), mp 2 one two gas one 4 (N, N — bis (2 oxazoline and 3-cyclopropyl-5 — isoradon 18- This paper scale is common to the Chinese Western Standard (CNS> A 4 specifications (210 X 297 gongs »81.9.20,000 Ministry of Central Standards Administration. «Industry and consumer cooperation Thorium seal 5 < f · A6, B6 V. Description of invention (Ir) The preparation of methyl 1, 2, 4- gas diazoxide; 7 — atmosphere 3 — (3 -Cyclopropyl 1, 2, 4-gas diazenium-5-yl)-5-(N-(1, 3-dioxane-2-yl)-methyl-N- Methylamino) quinazoline [1, 5-sl] quinazoline (compound 9), mp 223-226C, consisting of 2, 6-diamine 4-(N-(1, 3-dioxane mono 2-yl) methyl-N-methylamino) -quinazoline and 3-cyclopropyl-5-iso-radonylmethyl-1, 2, 4 are prepared by gaseous diazepine; 3-(3 —Cyclopropyl-1, 2,4 monofluorodiazepine S — 5 —yl) — 7 —gas-5 morpholine quinazoline C1, 5 — a] oxazoline (compound 1〇), mp 243-2451 , Prepared from 2-gas-6-fluoro-4_morpholinyl-quinazoline and 3-cyclopropyl-5-isomylmethyl-1, 2, 4-oxodiazepine; ethyl 7-Fluoro-5-morpholinyl-quinazole [1,5-a] quinazoline-3-carboxylate (compound 11), mp 238-239t, composed of 2-ambient-6-fluoro-4- It is prepared from quinolinyl-quinazoline and ethyl isocyanate; isopropyl 7-chloro-5- (N- (1,3-dioxan-2-yl) methyl-N-methylamino) squint Azole [1, 5-a] quinazoline 3-carboxylate (compound 12), m.p. 1 3 5-1 3 7 TC, consisting of 2, 6- two gas one 4 one (N-(1 , 3 — Erninyuan_2_ group) -methyl-N-methylamino) quinazol tablets and isopropyl isocyanoacetate prepared; -1 9- This paper is suitable for the West China standard (CNS) V 〇See grid (210 X 297 public goods) 81.9.20.000 ------------------------ installed ------. TΓ ------. ^. (Please read the notes on the back of Qi first, and then write this page) 0 0 Central Bureau of Standards, Ministry of Economic Affairs R Gongxiao Φ Cooperation Thorium Seal 5th Generation Α6 Β6 V. Description of Invention (ις) 9 One atmosphere 3 — (3-cyclopropyl 1, 2, 4 — gas diazenium -5- monoyl) — 5-morpholine quinazoline [1, 5-a] oxazoline (compound 13), m.p. 121-124C, cracked by 2, 8 — dioxin-4 4-garolinyl_quinazoline and 3_cyclopropyl-5-isocyanomethyl-1, 2, 4_oxodi MS Prepared; 9-Gas 3-(3-Cyclopropyl-1, 2, 4-Gas diazepine-5 monoyl)-5-(4-Methyl-1 1 pair of diazahexyl) [1, 5-a] quinoline (compound 14), m.p. 1 9 9-20 It :, consisting of 2, 8-diamine mono 4-(4-methyl-1 1 one-to-two Azahexyl) -quinazoline and 3-cyclopropyl-5-isohydrogenmethyl-1,2,4-gas diazide S Prepared; 6, 9- dichloromethane 3-(3-cyclopropyl 1, 2, 4-oxodioxi 5-5-yl)-5-morpholine-azoazole [1, 5-a] Quinazoline (compound 15), m.p. 1 8 4-1 8 6 ° C, from 2, 5, 8-three atmosphere _ 4-quinolinyl quinazoline and 3-cyclopropyl-5- Isohydromethyl-1, 2, 4-oxodiazepine S is prepared; 7-gas-3 (5-methylaminomethyl-1,2,4-gasdiazepine-3-yl) -5 -(N-ethyl-N-methylamino) quinazoline [1,5-a] quinililine (composite tree 16) P. 169-1 7 2 t :, from 2, 6-diamine-4 -(N-methyl-N-ethylamino) -quinazoline and 3-isocyanomethyl-5-methoxymethyl-1, 2, 4-oxodiazepine; 3 — (3-Cyclopropyl 1, 2, 4-gas diazenium-5-yl) 1-20- This paper scale is applicable to the Chinese and Western National Standards (CNS) Jia 4 said grid (210 X 297 public goods) 81.9. 20.000 ------------------------ Pretend ------, 玎 ------ ^ (Recognize the first reading-the note on the back (If you are busy, please fill out this page)

經濟部中央標準局1^工消资合作社印*'1代 五、發明説明(I 1 ) 5 —硫代嗎啉一 6 —三氟化甲基一眯唑〔1, 5 — a]嗤 唑啉(化合物 17) ,m. ρ· 162 — 165t,由 2 一氛一 4 一硫代嗎啉基一 5 —三氟化甲基一喔唑啉和3 — 環丙基一5—異氡基甲基一1, 2, 4—氧二氮S裂備而 得; 3 - (5 -環丙基一1, 2, 4 -氣二氮茂一 3 -基)一 5 —硫代嗎啉一 6 —三氟化甲基一眯唑〔1, 5 — a]喔 唑啉(化合物 18) , τη. P. 155 — 158 = ,由 2 一氛一 4 —硫代嗎啉基一 5 -三氣化甲基一喹唑啉和5_ 環丙基—3 -異氣基甲基一1, 2, 4 —氣二氮茂製備而 得; 6 —氛基一3 — (5 —環丙基一 1, 2,4 一氧二氣茂一 3-基)一5—嗎啉一眯唑〔1, 5—a〕喹唑啉(化合 物 19) ,m. ρ· 184— 187^0,由 2 —氣一5 — 氛基—4 一嗎啉基一喹唑啉和5 —環丙基一 3 —異氛基甲 基一 1, 2, 4 —氧二氮S製備而得; 3 — (3 —環丙基—1, 2, 4 —氣二氣 S — 5 —基)一 6 -氟一 5 —嗎啉一眯唑〔1 , 5 — a ]喹唑啉(化合物 20) , m . p . 2 1 6 - 2 1 8 °C ,由 2 — 氛一5 — 氟 一 4 一嗎啉基一喹唑啉和3 —環丙基一 5 —異氡基甲基一 1, 2, 4 —氣二氮茂製備而得; 3 — (5 — 環丙基—1,2, 4 — 氣二氮 S — 3 —基)一 6 -氟一 5 —嗎啉一眯唑〔1. 5 - a〕喹唑啉(化合物 -2 1- 本紙張尺茂適用中aa家標準(CNS)甲4規格(210 X 297公货) 81.9.20,000 ------------------------裝------,玎------Φ. (請先閲-背面之注念事項再填寫本頁) 經濟部中央標準局员工消費合作;:一印焚 A6 B6 五、發明説明(丨Ϋ ) 2 1 ) > m • P • 2 〇 4 一 2 〇 7 X: 由 2 — 氣 一 5 — 氣 — 4 一 嗎 啉 基 — 喹 唑 啉 和 5 — 環 丙 基 — 3 — 異 氡 基 甲 基 — 1 » 2 > 4 — 氣 二 m m 製 備 而 得 3 一 ( 3 — 環 丙 基 — 1 > 2 » 4 — 氧 二 氮 — 5 — 基 ) — 6 — 氟 一 5 一 ( 順 — 2 » 6 — 二 甲 基 嗎 啉 ) — 眯 唑 r 1 t 5 — a j 喹 唑 啉 ( 化 合 物 .2' 2 ) t m - P • 1 S 7 一 1 8 8 > 由 2 — 氣 — 5 — 热 — 4 — ( 順 一 2 t 6 — 二 甲 基 暍 啉 基 ) — 喹 唑 啉 和 3 — 環 丙 基 — 5 — 異 % 基 甲 基 — 1 » 2 > 4 — 氣 二 η 裂 備 而 得 3 — ( 3 — m 丙 基 — 1 1 2 > 4 — 氧 二 氮 茂 — 5 — 基 ) — 6 — m — 5 — 硫 代 嗎 啉 一 眯 唑 C 1 5 — a ] 喹 唑 啉 ( 化 合 物 2 3 ) » m • P • 2 5 2 — 2 5 3 » 由 2 — 氛 — 5 — 氟 — 4 — 碕 代 嗎 啉 基 — 喹 唑 啉 和 3 —* 環 丙 基 — 5 — 異 氛 基 甲 基 — 1 , 2 » 4 — 氧 二 氮 製 備 而 得 3 — ( 3 — 環 丙 基 — 1 t 2 > 4 — 氣 二 氮 茂 — 5 — 基 ) — 6 一 氟 — 5 — ( 4 — 甲 基 — 1 — 對 二 氮 己 環 基 ) — 眯 唑 C 1 * 5 — a ] 喹 唑 啉 ( 化 合 物 2 4 ) m • P 2 5 8 — 2 6 0 » 由 2 — 氟 — 5 — 氣 — 4 — ( 4 — 甲 基 — 1 — 對 二 m 己 環 基 ) — 喹 唑 啉 和 3 — 環 丙 基 — 5 — 異 % 基 甲 基 — 1 > 2 > 4 — 氣 二 氮 製 備 而 得 3 — ( 5 — 環 丙 基 — 1 > 2 » 4 — 氧 二 氮 — 3 — 基 ) — 5 一 ( 反 一 2 » 5 — 二 甲 基 嗎 啉 ) — 6 — — 眯 唑 C 1 » 5 一 a 3 喹 唑 啉 ( 化 合 物 2 5 ) > m P 2 0 8 — 2 1 -22- ------------------------裝------tr------線 (請先閲¾背面之注*事項再填寫本頁) 本纸張尺攻適用中國S家標準(CNS)甲4现格(210 X 297公釐) 81.9.20,000 五、發明説明(丨1) <請先閲汸背面之;±念事項再填寫本頁)Printed by the Central Bureau of Standards of the Ministry of Economic Affairs 1 * printed by the China Consumers ’Cooperation Fund * '1. V. Description of the invention (I 1) 5 —thiomorpholine-6 —trifluoromethyl monobenzotriazole [1, 5 — a] oxazole Porphyrin (Compound 17), m. Ρ · 162 — 165t, consisting of 2 — 4 — thiomorpholinyl — 5 — trifluorinated methyl oxazoline and 3 — cyclopropyl — 5 — isoradon Methyl-1,2,4-oxodinitrogen S is prepared by cracking; 3- (5-cyclopropyl-1,2,4-gas diazenium-3-yl) -5-thiomorpholine-6 —Trifluorinated methyl quinazoline [1, 5 — a] oxazoline (Compound 18), τη. P. 155 — 158 =, by 2-a 4-thiomorpholinyl 5-three gas Prepared by methyl quinazoline and 5-cyclopropyl-3-isogasylmethyl-1, 2, 4-pyrazine; 6-amino-3- (5-cyclopropyl-1 , 2,4 oxydioxa-3-yl) -5-morpholine-quinazoline [1,5-a] quinazoline (Compound 19), m.ρ · 184-187 ^ 0, from 2-gas A 5-amino group-4 morpholinyl-quinazoline and 5-cyclopropyl-3-isoaminomethyl-1, 2, 4-oxodiazepine S prepared; 3 — (3 — ring Propyl-1 , 2, 4-gas two gas S-5-yl)-6-fluoro-5-morpholine quinazoline [1, 5-a] quinazoline (compound 20), m. P. 2 1 6-2 At 1 8 ° C, it is prepared from 2-fluoro-5-fluoro-4-morpholinyl-quinazoline and 3-cyclopropyl-5-iso- radonylmethyl-1, 2, 4-gas diazoxide Get; 3-(5-cyclopropyl-1, 2, 4, 4-gas diazo S-3-yl)-6-fluoro-5-morpholine-myrazole [1.5-a] quinazoline (compound -2 1- This paper ruler is suitable for AA standard (CNS) Grade 4 specifications (210 X 297 public goods) 81.9.20,000 --------------------- --- Installation ------, 玎 ------ Φ. (Please read first-the notes on the back and then fill in this page) Employee consumption cooperation of the Central Standards Bureau of the Ministry of Economic Affairs ;: Yiyin A6 B6 V. Description of the invention (丨 Ϋ) 2 1) > m • P • 2 〇4-2 〇7 X: from 2-gas-5-gas-4-morpholinyl-quinazoline and 5-cyclopropyl — 3 — Isoradyl methyl — 1 »2 > 4 — gas two mm prepared to get 3 one (3 — cyclopropyl — 1 > 2» 4 — oxydiazepine — 5 Radical) — 6 — fluoro- 5 mono (cis — 2 »6 — dimethylmorpholine) — zonazo r 1 t 5 — aj quinazoline (compound .2 '2) tm-P • 1 S 7-1 8 8 > from 2 — gas — 5 — heat — 4 — (cis 2 t 6 — dimethylchrysolinyl) — quinazoline and 3 — cyclopropyl — 5 — iso% ylmethyl — 1 »2 > 4 — gas di η cracked to prepare 3 — (3 — m propyl — 1 1 2 > 4 — oxydiazepines — 5 — yl) — 6 — m — 5 — thiomorpholine-triazole C 1 5 — a] Quinazoline (Compound 2 3) »m • P • 2 5 2 — 2 5 3» From 2 — atmosphere — 5 — fluorine — 4 — benzomorpholinyl — quinazoline and 3 — * Cyclopropyl — 5 — isoamidomethyl — 1, 2 »4 — oxydiazepine is prepared from 3 — (3 — cyclopropyl — 1 t 2 > 4 — gas diazono — 5 — group) — 6 monofluoro— 5 — (4 — methyl — 1 — p-diazepine) — zonazo C 1 * 5 — a] Quinazoline (compound 2 4) m • P 2 5 8 — 2 6 0 »from 2 — fluorine — 5 — gas — 4 — (4 — methyl — 1 — p-dim hexyl) — quinazoline and 3 — cyclopropyl — 5 — Iso% ylmethyl — 1 > 2 > 4 — prepared by gaseous diazide to give 3 — (5 — cyclopropyl — 1 > 2 »4 — oxydiazepine — 3 — yl) — 5 one (Reverse 2 »5 — dimethylmorpholine) — 6 — — zonazole C 1» 5 a 3 quinazoline (compound 2 5) > m P 2 0 8 — 2 1 -22- --- --------------------- install ------ tr ------ line (please read the note on the back of ¾ * items before filling this page ) This paper ruler is applicable to the Chinese S Family Standard (CNS) Grade A 4 (210 X 297 mm) 81.9.20,000 V. Description of the invention (丨 1) < Please read the back of the Qi; please fill in the matters before the reading (This page)

Ot.由2—氛一5—氟一4一 (2, 5—二甲基嗎啉基 )一喹唑啉和5 —環丙基一 3 —異m基甲基一 1, 2, 4 一氣二氮茂製備而得;化合物2 5是由化合物2 6中以管 柱層析分離而得,(洗灌劑:醋酸乙酯:丙酮(2 : 1) ); 3 - (5 —環丙基一 1,2, 4 —氧二氮茂一 3 —基)- 5 —(順一 2, 5_二甲基嗎啉)一 6 —氟一眯唑〔1, 5 - a〕喹唑啉(化合物 26) , m . p . 186 — 18 9t,由2 -氛一 5 —氟一4 - (2, 5 -二甲基嗎啉基 )—喹唑啉和5 —環丙基一3 —異氛基甲基一1, 2, 4 一氧二氮S裂備而得;化合物26是由化合物25中以管 柱層析分離而得,(洗濯劑:錯酸乙酯:丙嗣(2 : 1) ); 3 — (3 —環丙基一 1, 2, 4 —氣二氮 S — 5 —基)一 8 -氟一 5 -嗎啉基一眯唑〔1, 5 — a]喹唑啉(化合 物 2 7) , m . p . 276-27810.由 2 -氯一 7 — 氣-4一嗎啉基一嗤唑啉和3—環丙基一5—異氡基甲基 —1, 2, 4 -氧二氮S裂備而得; 經濟部中央 '標準居員工消资合作钍印架 3 — (3 —環丙基一1, 2, 4 -氣二氪茂一5 —基)一 5 - (3, 3 —二甲基暍啉)一7 —氟一眯唑〔1, 5 — a〕喹唑啉(化合物28) , m . p. 259C,由2 — 氯一 6 —氟一 4 一 (3, 3 —二甲基嗎啉基)一喹唑啉和 3_環丙基一 5 —異氡基甲基一 1, 2, 4 —氣二氮茂裂 -23- 81-9.20.000 表纸張尺茂適用中西S家i?準(CNS〉甲4现格(210 X 297公:S ) 垤濟邡中夹標準局1*工消费合作社印« iiotiO A6 _^_B6_ 五、發明説明Uo) 備而得; 3 — (3_環丙基一 5 —異噁唑)一6 —氟一 5 —嗎啉基 -眯唑〔1, 5 — a〕喹唑啉(化合物29) , m. ρ· 208 — 2 1 0C,由2 -氛—5 -氟一4 一嗎啉基一喹 唑啉和3 -環丙基- 5 —異氡基甲基一異噁唑製備而得; 3 - (5 — 環丙基一1, 2·, 4— 氧二氮 S—3—基)— 5 - (3, 3-二甲基嗎啉)一7 -氟一眯唑〔1, 5 — a〕喹唑啉(化合物 30) , m. Ρ. 251 — 254¾ ,由2—氛一6—氟一4-(3. 3—二甲基嗎啉基)一 喹_啉和5_環丙基_3-異氣基甲基一 1, 2, 4 —氣 二氮茂裂備而得; 叔-丁基6-氣-5-嗎啉-眯唑〔1, 5-a〕喹哩琳 _3_ 羧酸醑(化合物 31) ,m. P. 19 1-19 3 °C,由2 —氧一 5 —氟一 4 —嗎啉基一喹唑啉和叔-丁基 異氡基乙酸酯裂備而得; 3 — (5 —環丙基一1, 2,4 —氯二氮茂一 3 —基)- 7 —氣一 5 — (4 一甲基一 1—對二氮己環基)一眯唑〔 1, 5-a]喹唑啉(化合物 32) , m . p . 2 0 2 - 2 0 4 ^,由 2 —氛一 6 — 氟一 4 一 (4 -甲基一 1-對 二氮己環基)_喹唑啉和5 —環丙基一 3 —異氡基甲基一 1,2, 4 —氣二氮茂製備而得; 3 - (3 — 環丙基一 1, 2,. 4 —氣二氮 S — 5 — 基)— 5 - ( N - (1, 3 -二噁烷一2 —基)甲基一N -甲基 -24- 本纸張尺度通用中西a家櫺準(CNS〉甲4现格(210 X 297公釐) 81.9.20,000 ------------------------裝------ΤΓ------線 (掎先閲边背面之注念事項再塡寫本頁) 五、發明説明(i| ) Α6 B6 胺基)一 6 —氟一眯唑〔1, 5 - a〕喹唑啉(化合物3 3) , m . p . 2 0 9 - 2 1 It:,由 2 — 氨一 4 一 (N 甲基一 N —甲基胺基)一 5 —異氰基甲基一 1, 2 3 -( 5 -氟一 _哩 .4 —氣二氮 3 - ( 5 -環 5 -( 二噁烷 啉和3 S製備 —2 —基) —環丙基一 -a ] °C ,由 喹唑啉 3 , 3 喹唑啉 丙基一 -二甲 而得; 1 , 2. , 4 基嗎啉基) (化合物3 4 ), 2 -氛 和5 —環丙基 —4 — (3 , 3 — 一 3 _異氛 一氧二氮茂一3—基)一 一6-氟一眯唑〔1, 5 m P . 210 — 212 二甲基嗎啉)一5_氟一 基甲基一 1, 2, 4 —氧 二氮S裂備而得; 3 -( 5 -( 脞〔1 5 —環丙基一 1, 2, 4— m 二氮 S — 3 — 基)— 順一2, 6—二甲基—1—呢旋基)一6—氣一昧 ,5 — a ]喹唑琳(化合物3 5 6 4 t: m . p . 6 3-1 1 一呢疲基)—5 ,由2 —氣一4 一 娌濟部中央標準总員工消if合作社印¾ 氟—喹唑啉 一氣二ms製備而得; 1,2,4 7 —氟一 5 —硫代媽啉一眯唑〔 2 , 4 基甲基_ 1, 3 — ( 5 _環丙基 (順一 2, 6 —二甲基一 和5_環丙基一 3 —異氡 氣二SS_3_基)— 1 , 5 — a〕喹唑啉(化 235t,由 2 — 氛一 6 5 —環丙基一 3 —異氣基 合物 36) , m . p . 2 3 3 - 一氟一 4 _硫代嗎啉-嗤唑啉和 甲基一 1, 2, 4 —氧二氮茂製備而得; 3 - (3 —環丙基一 1, 2, 4-氣二氮茂一5 —基) -25- 本紙張尺度適用中aa家標準(CNS)甲4现格(210 X 297公货) 81.9.20,000 -------------------1-----装------,玎------線 (請先閲汸背面之注念事哨再塡寫本頁) i咖 A6 B6 五、發明説明(iij 5 - (4 一甲基一 1 一對二氮己環基)一 6 一眯唑 氟化甲基 [1,5 ,m . p .在 3 基一1 >jy:i — tas —對— 基一5 — —a]喹唑啉,氫氛化物(化合物37) OOt時分解,由2 —氛一4 - (4 一甲 己環基)一5_三氟化甲基一嗤唑啉和3 異氡基甲基一 1, 2, 4 — _環丙 而得;氫氛化物是由將鹼溶解入甲撐氣化物 氫而形成。 乙基6—氰一5—暍啉一眯唑〔1, 5—a 酷(化合物38) , m . p . 196 氣二氮茂製備 中且加入氛化 〕喹唑啉一 3 -1 9 8 它, 一羧酸 由2 —氛一 5 —氟一 4_嗎啉一嗤唑啉和異氡基乙酸乙酯 反應裂備而得; 基一1, 2, 4 -氧二氮茂 1_對二氮己環基)一 6_三氣化甲基 一 a〕唼唑啉,氫氛化物(化合物39) 〇0t:時分解,由2 —氛一 基一1 一對二氮己環基)一 5 —三氟化甲基 -環丙基一 3 —異氛基甲基一1, 2, 4 — 3 -( 5 -( 一眯唑 m 5 —環丙 4 一甲基 〔1,5 P .在2 -3 —基)_ 4 - ( 4 -甲 -喹唑啉和5 m二氮茂製備 而得;氫氯化物是由將鹼溶解入甲撐氱化物中且加入氣化 (请先閲汸背面之注念事項再填寫本頁) 經濟部中央標準尽員工消费合作社印焚 氫而形成。 3 — ( 3 —環丙 5 -(反-2 , 5 — a〕喹唑啉(化合物40) 基一 1, 2, 4 -氧二氮S 5—二甲基皞啉)一6_氟 m . p . 4 1C ,由 2 -氛一5 -氟一4 - (2, 5 -2 6 - _ 5 _ 基)-一眯唑〔1 , 2 11-21 二甲基嗎啉) 本纸張尺度適用tfflS家«準(CNS)甲4现格(210 X 297公S ) 81.9.20.000 烴濟部中央標準局員工消費合作社印¾ lioto A6 B6 五、發明説明(θ ) — 嗤 唑 啉 和 3 — 環 丙 基 一 5 一 異 基 甲 基 — 1 t 2 » 4 一 氣 二 氮 製 備 而 得 « 化 合 物 4 0 是 由 化 合 物 4 1 中 以 管 柱 層 析 法 分 離 而 得 > ( 洗 提 劑 : 甲 撐 氮 化 物 : 醋 酸 乙 酯 1 : 1 ) ) ) 3 — ( 3 — 環 丙 基 — 1 > 2 » 4 — 氣 二 氮 — 5 — 基 ) — 5 — ( 順 — 2 » 5 — 二甲基嗎啉) — 6 — 氟 — 眯 唑 C 1 » 5 — a ] 嗤 唑 啉 ( 化 合 物 4 1 ) » m • P • 1 6 9 — 1 7 1 » 由 2 — 氛 — 5 — 氟 — 4 — ( 2 5 — 二甲基嗎啉) — 喔 唑 啉 和 3 — 環 丙 基 — 5 — 異 m 基 甲 基 — 1 > 2 > 4 — 氧 二 氮 S 製 備 而 得 < 化 合 物 4 1 S 疋 由 化 合 物 4 0 中 以 管 柱 層 析 1 法 Ί 分 離 而 得 ( 洗 提 劑 甲 撐 化 物 醋 酸 乙 酷 ( 1 3 丄 ) ( ) 5 * 環 丙 基 — 1 » 2 4 氯 二 氮 S — 5 — 基 ) — 5 一 ( N — ( 1 t 3 — 二 噁 院 — 2 — 基 ) 甲 基 — N 一 甲 基 胺 基 ) — 6 — 氟 — 眯 唑 r t 1 > 5 — a ] 喹 唑 啉 ( 化 合 物 4 2 ) f m • P • 1 8 4 — 1 8 6 V > 由 2 — 氛 — 4 — ( N — ( 1 > 3 — 二 m 院 — 2 — 基 ) 甲 基 — N — 甲 基 胺 基 ) — 5 一 氟 — 喹 唑 啉 和 5 — 環 丙 基 — 3 — 異 氰 基 甲 基 — 1 » pi > 4 — 氧 二 氮 S 製 備 而 得 > 3 — ( 3 一 環 丙 基 — 1 > 2 9 4 — 氣 二 氮 m — 5 — 基 ) 一 5 一 ( 順 — 2 » 6 — 二 甲 基 — 1 — 啶 基 ) — 6 — 氟 — 眯 唑 ί 1 I 5 — a ] 喹 唑 啉 ( 化 合 物 4 3 ) m • P • 1 3 2 — 1 3 4 * 由 2 一 氣 一 4 一 ( 順 一 2 * 6 — 二 甲 基 一 -27- ------------------------装------,ΤΓ------線{諳先閲洁背面之注念事項再塡寫本頁) 木纸張尺茂通用中困西家櫺準(CNS)甲4现格(210 X 297公;$) 81.9.20.000 五、發明説明()4) A6 B6 1一顿啶基)一5—氟一嗤唑啉和3—環丙基一5—異氡 基甲基一1, 2,4_氣二ms製備而得; 3 — (3 — 環丙基一 1, 2, 4 — 氣二氮 S—'5 — 基)一 5 - (3, 3 -二甲基嗎啉基)-6 —氟一眯唑〔1, 5 a °C ,由 喹唑啉 3 , 3 喹唑啉 2 -氛 和3 - (化合物 44) , m . p . 2 (3,‘3-二甲基嗎啉 4 4 - 2 4 6 )一 5 _ 氣一 環丙基一 5 —異氡基甲基一 1, 2, 4 —氣 -4 - 二氣茂製備而得; (請先閲汸背面之注念事項再塡寫衣頁) 縵濟部中央標準尽員工消费合作让印焚 3 -( 5 -( 7 —氣 .p · -(2 3 -環 備而瘩 實洌3 6 —氣 -基) 唑啉 3 -環 N -( -眯唑〔1 , 17 0-17 一二甲基胺基 丙基一 5 —異 丙基一 1, 2, 4_m二氟s 2 —二甲基胺基乙基)一 N-〔1 , 5 — a〕喹唑啉(化合 2t,由 2 -氛一 6-乙基)一N—乙基胺基 氛基甲基一 1 , 2,4 —5 _ 基)一 乙基胺基)一 物 4 5 ) , m 氰-4 - ( N )一喹唑啉和 一氣二氮茂製 -3 - (3 -環丙基-1, 2, 4 —氣二氮茂一 5 一 4, 5 — 二氫一5 —氧一眯唑〔1, 5 — a〕喹 將6 —氛一3 — (3 —環丙基一1> 2 4 氧二氮 茂_5—基)一5—嗎啉一眯唑〔1, 5-a〕 一喹唑啉 (1. 45g)溶於25ml的6MM氛酸 在45K:下《拌45分鐘,然後将混合物冷 水溶液中,且 却至0 t:及過 28- 本纸張尺及適用中國四家標準(CNS)甲4規格(210 X 297公;$) 81.9.20,000 Α6 Β6 五、發明説明(〗Γ) 濾 出 沈 澱 物 > 在 過 薇 器 上 以 2 5 m ! 的 水 及 以 5 X 1 m 1 的 醋 酸 乙 酯 > 最 後 用 1 0 m 1 的 二 乙 m 洗 m > 乾 燥 结 晶 産 掬 > 可 得 〇 • 8 5 S 的 標 題 ί匕 合 物 t m • P - 2 7 0 — 2 7 2 V ( 分 解 ) 〇 以 類 似 的 方 式 製 備 下 列 化 合 物 3 — ( 5 — 環 丙 基 一 1 > 2· > 4 一 氯 二 氮 茂 — 2 — 基 ) — 6 — 氟 — 4 5 一 二 氫 一 5 — 氣 — 眯 唑 r 1 » 5 — a ] 瘦 唑 啉 » m • P • 2 6 〇 — 2 6 4 V ( 分 解 ) 由 水 解 3 一 ( 5 — 環 丙 基 — 1 f 2 1 4 一 氧 二 m — 3 一 基 ) 6 — 氟 — 5 — ( 3 5 一 二 甲 基 嗎 啉 ) 眯 唑 — r L 1 » 5 一 a j 喹 唑 啉 而 得 1 3 — ( 5 — 環 丙 基 — 1 » 2 » 4 — m 二 氮 δ — 3 — 基 ) — 7 — 氣 — 4 5 一 二 Μ 一 5 — 氣 — 眯 唑 C 1 > 5 — a 嗤 唑 啉 » m P • 〇 5 4 — 2 5 5 ♦ 由 水 解 3 — ( 5 — 環 丙 基 一 1 贅 2 t 4 — 氯 二 氪 m — 3 — 基 ) — 7 一 氟 — 5 — ( 3 » 2 一 二 甲 基 嗎 啉 ) 眯 唑 —— [ 1 t 5 一 a J 喹 唑 啉 而 --------------------------裝------.玎------線 <諳先閲^背面之;±念事-';*堉寫本1) 煙濟部中央標準局MS工消費合作社印¾ 得; 霣例4 5, 6—二氣一3— (3—環丙基一1, 2, 4—氧二氣 茂一 5_基)一眯唑〔1, 5_a〕喹唑啉 —IS拌的混合物,包含有6 —氛—3 — (3 -環丙基 -1, 2, 4 — 氧二氪茂一 5 — 基)一 4, 5 -二氫一 5 一氧一眯唑〔1, 5 — a]喹唑啉(1. Og),三丙基 -29- 本纸張尺度i4用中西因家標準(CNS)甲4现格(210 X 297公货) 81.9.20,000 ΐΑιή,。 Α6 Β6 娌濟部中央標準局g工消費合作社印5代 五、發明説明) 胺 ( 〇 • 5 m 1 ) 和 氧 氣 化 m ( 5 m 1 ) » 在 1 4 〇 一 1 5 0 下 加 熱 〇 1 小 時 後 » 再 加 入 P 0 C 1 2 ( 5 m 1 ) 和 三 丙 基 胺 ( 0 * 5 m 1 ) » 且 持 缠 加 熱 1 * 5 小 時 9 然 後 將 此 溫 熱 的 混 合 物 倒 入 2 0 0 m 1 的 水 中 9 且 激 烈 的 m 拌 〇 1 5 分 鐘 後 > 加 入 1 0 〇 m 1 的 二 氱 甲 烷 > 過 濂 收 集 不 能 溶 解 的 物 質 » 以 二 乙 酸 洗 灌 9 乾 燥 後 可 得 標 題 化 合 物 » 其 為 黃 褐 色 的 結 晶 物 〇 m • P * 2 3 8 — 2 4 〇 » 産 率 0 • 4 7 〇 以 頚 似 的 方 法 製 .備 下 列 化 合 物 5 — 氛 — 3 — ( 5 — 環 丙 基 — 1 > 2 * 4 — 霉 二 — 3 一 基 ) — 6 — m — 眯 唑 C 1 » 5 — a ] — 喹 唑 啉 » 由 3 — ( 5 — 環 丙 基 — 1 , 2 » 4 一 氣 二 氮 茂 — 3 — 基 ) — 6 — 氣 — 4 > 5 — 二 氫 — 5 — 氣 一 眯 唑 C 1 » 5 — a J 喹 唑 啉 製 備 而 得 , 5 — 氛 — 3 一 ( 5 — 環 丙 基 一 1 > 2 > 4 — 氣 二 氮 S — 3 一 基 ) — 7 — 氟 — 眯 唑 [ 1 * 5 — a ] — 喹 唑 啉 » m » P * 2 4 9 — 2 5 1 t > 由 〇 — ( 5 — 環 丙 基 — 1 y 2 > 4 — 氧 二 氮 — 3 — 基 ) — 7 — 氟 — 4 , 5 — 二 氧 — 5 — 氧 一 眯 唑 Γ 1 9 5 — a 3 喹 唑 啉 裂 備 而 得 實 例 5 ( R ) 一 6 一 m — 3 — ( 3 — 環 丙 基 — 1 > 2 t 4 — m 二 気 茂 — 5 — 基 ) — 5 — ( 2 一 羥 基 甲 基 — 1 — at 咯 烷 基 ) — 眯 唑 C 1 » 5 一 a ] 喹 唑 啉 ( 化 合 物 4 6 ) -30- (請先閲讀背面之注念事項再塡寫木頁) 本紙張尺·度適用中a西家櫺準(CNS) Ψ 4现格(210 X 297公:S ) 81.9.20.000 A6 B6 五、發明説明U1")) 一混合物,包括 mg)和三乙胺(9 )中,其是以液滴的 (3 -環 ί 1 , 5 F ( 5 m 濾反睡混 1 0分鐘 可得標題 2 2 1 V 以類似的 6 _氣― -基)— 丙基一 1 , —a〕—喹 1 )的懸浮 合物,濂液 。過濂出所 化合物,其 ,産宰0 . 方法裂備下 3-(3- 5 —硫代嗎 合物 4 7 ) , m · p (R ) 一 2 —羥基甲基吡咯垸(70 0 m g )溶解於無水DMF (1ml 方式加至一包含5, 6 —二氛一 3 - 2, 4 -氣二氮茂一5 -基)一眯唑 唑啉(0. 20s)溶解於無水DM 液中,‘溫度為Ot:。20分鐘後,過 以1 5m 1的水稀釋及在Ot:下it拌 形成的結晶産物,以水洗濯,乾燥後 為黃色的结晶物。m. p. 22 Ο-ΐ 5 g 。 列化合物: 環丙基一 1, 2, 4 —氣二氣S_5 啉一眯唑〔1 , 5 — a〕嗤唑啉(化 .24 0 - 241C,由 5, 6 -二 氛-3 -)一眯唑 6 —氣_ (3 —環丙基_1,2, 4 —氧二氣茂一 5 —基 ,5 3-(3- ------------------------装------,ΤΓ------線 (锖先閲汸背面之注念事項再填寫本頁> a〕喹唑啉和硫代嗎啉裂備而得 經濟部中央標準局tH工消費合作社印¾ 環丙基一 1 , 2 , 一基)一 5 — (順一 2, 6 -二甲基嗎 a〕喹哩啉(化合物48) , m ,5 4 一氣二氣S 啉基)一眯唑 .p . 2 3 6 -5 2 3 8 ,由 5 , 6 - mit rr 戊—亡— 6 _二甲基嗎啉製備而得; 4 _氣二 順 2 , 二氣一 3 — (3 —環丙基_1,2, 基)-眯唑〔1 , 5 — a ]喹唑啉和 (S ) 一 6 — 氣一 3 — (3 —環丙基一1,2,4 3 1 木纸張尺度適用中a西家標準(CNS>甲4规格(210 X 297公货) 氧 81.9.20,000 經濟部中夹櫺準居8工消費合作社印% A6 B6 五、發明説明(Μ ) 氮茂一5 —基)一 5 — (2 —甲氣基甲基_1_吡咯烷) 一眯唑〔1,5_a〕喹唑啉(化合物49) , m. p. 266 — 269 °C,由 5, 6 — 二氮 一3_ (3 — 環丙基 一 1,2, 4 —氧二氣茂一基)一味唑〔1, 5 — a 〕喹唑啉和(S) _2 —甲氧基甲基吡咯烷裂備而得; (S) - 6 — 氱一3 — (3 —環丙基一 1, 2, 4 —氧二 第茂一5 —基)一5 — (2 —理-基甲基一1— (ft塔院基) 一眯唑〔1. 5 - a]喹唑啉(化合物50) , m. P. 230 — 232t,由 5, 6 -二氯 - (3 — 環丙基 —1, 2, 4_ 氧二氣茂一 5 —基)一味哩〔1, 5 — a 〕喹唑啉和(s) - 2—羥基甲基at咯烷裂備而得; 6 - m - 3 - (3_ 環丙基一 1, 2, 4 — 氯二氰茂 一 5 一基)一5— (3-羥基一1一锨啶基)一眯唑〔1, 5 一 a]喹唑啉(化合物 51) , m. P. 258-261 由 5, 6 — 二氣一3 — (3_摄丙基一1, 2 , 4 — «二氮茂一 5 -基)—眯唑〔1, 5 — a〕嗤唑啉和3 — 羥基帮啶製備而得; 6 — 氯-3 — (3 -環丙基一 1, 2, 4 - 氯二氮 S-5 一基)—5- (4_苯基一 1 一對二氮己環)一眯唑〔1 ,5-a〕唾唑淋(化合物52), m. ρ· 255-2 57t:,由 5, 6 -二氛一 3 — (3 — 環丙基一1, 2, 4 -氣二氮S — 5 —基)一眯唑〔1, 5 — a〕喹唑啉和 1_苯基對二氮己琛製備而得; -32- .纸張尺度適用中囲Η家標準(CNS>甲4现格(210 X 297公釐) 81.9.20.000 ------------------------装------tr------線 (請先閲汸背面之注念事項再填寫本頁)Ot. Consists of 2-ambient 5-fluoro-4 4- (2,5-dimethylmorpholinyl) -quinazoline and 5-cyclopropyl-3-isomylmethyl-1, 2, 4 in one gas It is prepared by diazoxide; compound 25 is obtained from compound 26 by column chromatography, (lavage agent: ethyl acetate: acetone (2: 1)); 3-(5-cyclopropyl 1,2,4-oxodiazepine-3-yl) -5- (cis-2,5-dimethylmorpholine) -6-fluoro-quinazoline [1,5-a] quinazoline (Compound 26 ), m. p. 186 — 18 9t, consisting of 2-fluoro-5-fluoro-4- (2, 5-dimethylmorpholinyl) -quinazoline and 5-cyclopropyl-3-isohydrogen Methyl-1,2,4-oxodinitrogen S is prepared by cracking; compound 26 is obtained by column chromatography of compound 25, (washing agent: ethyl acetate: propionate (2: 1) ); 3 — (3-cyclopropyl-1, 2, 4-gasdiazepine S — 5-yl)-8-fluoro-5-morpholinyl-quinazoline [1, 5-a] quinazoline ( Compound 2 7), m.p. 276-27810. From 2-chloro-7-gas-4-morpholinyl-oxazoline and 3-cyclopropyl-5-isoradylmethyl-1, 2, 4-Oxydiazepine S is prepared by splitting; Ministry of Economic Affairs Central's standard residence staff consumption cooperation thorium printing frame 3-(3-cyclopropyl 1, 2, 4-gas dikrypium 5-yl)-5-(3, 3-dimethyl chrysoline) 7-fluoro-quinazoline [1, 5-a] quinazoline (compound 28), m.p. 259C, consisting of 2-chloro-6-fluoro-4 4- (3, 3-dimethylmorpholinyl ) A quinazoline and 3_cyclopropyl- 5-iso- radonyl methyl 1, 2, 4--gas diazocrack -23- 81-9.20.000 sheet paper is suitable for Chinese and Western S? Quasi (CNS> A 4 present grid (210 X 297 g: S) 垤 济 邡 中 採 測 標 樂 局 1 * Industry and Consumer Cooperatives printed «iiotiO A6 _ ^ _ B6_ Fifth, the invention description Uo) available; 3 — (3_ Cyclopropyl-5-isoxazole) -6-fluoro-5-morpholinyl-quinazoline [1,5-a] quinazoline (compound 29), m. Ρ · 208-2 1 0C, by 2 -Atmosphere-5-fluoro-4-morpholinyl-quinazoline and 3-cyclopropyl-5-iso- radonylmethyl-isoxazole; 3-(5-cyclopropyl-1, 2 ·, 4-oxodiazepine S-3-yl) — 5-(3, 3-dimethylmorpholine) -7-fluoro-quinazoline [1, 5-a] quinazoline (compound 30), m . Ρ. 251 — 254¾ By 2-ambient-6-fluoro-4- (3. 3-dimethylmorpholinyl) -quinoline and 5_cyclopropyl_3-isopropylmethyl-1, 2, 4--dichloro Nitrogen is prepared by cracking; tert-butyl 6-gas-5-morpholine-triazole [1, 5-a] quinileline _3_ carboxylate (compound 31), m.P. 19 1-19 3 ° C, prepared from 2-oxo-5-fluoro-4-morpholino-quinazoline and tert-butyl iso- radonyl acetate; 3 — (5-cyclopropyl-1, 2 , 4-chlorodiazepine-3-yl) -7-gas-5— (4-methyl-1-1-p-diazinocycloyl) quinazoline [1, 5-a] quinazoline (compound 32) , m. p. 2 0 2-2 0 4 ^, consisting of 2-amino-6-fluoro-4- (4-methyl-1-p-diazohexyl) _quinazoline and 5-cyclopropyl A 3-isoradonyl methyl 1,2, 4-gas diazepine prepared; 3-(3-cyclopropyl 1, 2, 4-gas diazo S-5-base)-5 -(N-(1, 3 -dioxane-2-yl) methyl-N-methyl-24- This paper scale is commonly used in Chinese and Western a-frame standard (CNS> A4 present grid (210 X 297 mm ) 81.9.20,000 ------------------------ installed ------ ΤΓ ------ line (read the back first) (I |) Α6 B6 amino group) 6-fluoro-quinazoline [1, 5-a] quinazoline (compound 3 3), m. P . 2 0 9-2 1 It :, from 2-ammonia-4-(N methyl-N-methylamino)-5-isocyanomethyl-1, 2 3-(5-fluoro one mile .4 —Gas diazepine 3-(5 -ring 5-(dioxaline and 3 S prepared —2-yl) —cyclopropyl mono-a] ° C, from quinazoline 3, 3 quinazoline propane Derived from the base one-dimethyl; 1, 2., 4-ylmorpholino) (compound 3 4), 2-ambient and 5-cyclopropyl-4 — (3, 3 — a 3 _isoventrious oxydio Nitrocyl-3-yl) -6-fluorofluoromazole [1, 5 m P. 210-212 dimethylmorpholine) -5_fluoro-ylmethyl-1, 2, 4-oxodiazepine S-crack Prepared; 3-(5-(脞 [1 5 -cyclopropyl-1, 2, 4-m-diazo S-3 -yl)-cis-2, 6-dimethyl-1-cyclopropanyl) A 6-qi Yimei, 5-a] quinazoline (compound 3 5 6 4 t: m. P. 6 3-1 1 a nerzyl)-5, by 2-Qi Yi 4 a central government Printed by Standard General Staff Cooperative Society ¾ Fluoro-quinazoline It is prepared by one gas and two ms; 1,2,4 7 -fluoro- 5 -thiophosphorinoline-conazole [2, 4 -ylmethyl _ 1, 3-(5 _ cyclopropyl (cis-2, 6-di Methyl one and 5_ cyclopropyl one 3-iso- radon gas di SS_3_ group)-1, 5-a] quinazoline (chemical 235t, from 2-atmosphere one 6 5-cyclopropyl one 3-different gas Base compound 36), m.p. 2 3 3-monofluoro 4 _ thiomorpholine-oxazoline and methyl one 1, 2, 4-oxydiazepine prepared; 3-(3- Cyclopropyl-1, 2, 4-gas diazenium-5-yl) -25- This paper scale is applicable to the aa family standard (CNS) Grade A 4 (210 X 297 public goods) 81.9.20,000 ---- --------------- 1 ----- installed ------, 玎 ------ line (please read the commemorative whistle on the back of 汸 first, then 塡Write this page) i Cafe A6 B6 V. Description of the invention (iij 5-(4 monomethyl-1 pair of diazacyclohexyl)) 6 monofluoroazole methyl fluoride [1,5, m. P .in. 3 yl 1 > jy: i — tas — p — yl 5 — a) quinazoline, the hydrochloride (compound 37) decomposes at OOt, from 2 — ambience 4-(4 monomethylhexyl ) A 5_ trifluoromethyl oxazoline and 3 iso- radonyl methyl 1, 2, 4 — _ It is derived from cyclic propylene; hydrogen oxygenate is formed by dissolving alkali into the hydrogen gas of the methylene chloride. Ethyl 6-cyano-5-naphtholine-azoazole [1,5-a cool (compound 38), m.p. 196 in the preparation of gaseous diazepines and the addition of volatile] quinazoline-3 -1 9 8 It, a carboxylic acid is prepared by the reaction of 2-fluoro-5-fluoro-4-morpholine-oxazoline and iso- radonyl ethyl acetate; the base is 1, 2, 4-oxaziridine 1_ pair Diazahexyl)-6_trigasified methyl-a] oxazoline, hydrogen atmosphere (compound 39) 〇0t: decomposes at the time, from 2-atmosphere one group-1 pair of diazahexyl groups) A 5-trifluoromethyl-cyclopropyl- 3-isocyanatomethyl 1, 2, 4-3-(5-(azole m 5-cyclopropyl 4- monomethyl [1, 5 P .In 2 -3 -yl) _ 4-(4 -methyl-quinazoline and 5 m diazepines are prepared; hydrochloride is made by dissolving the alkali into the methylene chloride and adding gasification (please first Read the notes on the back of the page and fill out this page) The Central Standard of the Ministry of Economic Affairs is formed by printing and burning hydrogen in a consumer cooperative. 3 — (3 —Cyclopropyl 5-(trans-2, 5 — a) quinazoline (Compound 40 ) Based on 1, 2, 4-oxydiazepine S 5-dimethyl oxaline) a 6_ fluorine m. P. 4 1C, from 2-atmosphere-5-fluoro 4-(2, 5 -2 6-_ 5 _ group) -anilazole (1, 2 11-21 dimethylmorpholine) This paper scale is applicable to tfflS home «quasi (CNS) A 4 present grid (210 X 297 public S) 81.9.20.000 Printed by the Employee Consumer Cooperative of the Central Standards Bureau of the Ministry of Hydrocarbon Economy lioto A6 B6 V. Description of the invention (θ) — oxazoline and 3-cyclopropyl- 5 -isopropylmethyl — 1 t 2 »4 nitrogen dioxide «Compound 4 0 was prepared by column chromatography from compound 4 1> (eluent: methylidene nitride: ethyl acetate 1: 1))) 3 — (3 — cyclopropyl Group-1 > 2 »4 — gas diazo — 5 — group) — 5 — (cis — 2» 5 — dimethylmorpholine) — 6 — fluoro — quinazoline C 1 »5 — a] oxazoline (Compound 4 1) »m • P • 1 6 9 — 1 7 1» From 2 — atmosphere — 5 — fluorine — 4 — (2 5 — dimethylmorpholine) — oxazoline and 3 — cyclopropyl — 5 — isomylmethyl — 1 > 2 > 4 — prepared from oxydiazepine < compound 4 1 S Compound 4 0 was obtained by column chromatography 1 method Ί separation (eluent methylalide ethyl acetate (1 3 丄) () 5 * cyclopropyl — 1 »2 4 chlorodiazepine S — 5 — Group) — 5 a (N — (1 t 3 — dioxin — 2 — group) methyl — N monomethylamino group) — 6 — fluoro — zonazo rt 1 > 5 — a] quinazoline ( Compound 4 2) fm • P • 1 8 4 — 1 8 6 V > from 2 — atmosphere — 4 — (N — (1 > 3 — 二 m 院 — 2 — group) methyl — N — methylamine Radical) — 5 monofluoro-quinazoline and 5-cyclopropyl-3 — isocyanomethyl — 1 »pi > 4 — prepared from oxydiazepine S> 3 — (3 monocyclopropyl-1 > 2 9 4 — gas diazo m — 5 — yl) mono 5 -1 (cis — 2 »6 — dimethyl — 1 — pyridyl) — 6 — fluoro — mesoazole 1 I 5 — a] quinazole Porphyrin (compound 4 3) m • P • 1 3 2 — 1 3 4 * from 2 one gas one 4 one (cis one 2 * 6 — dimethyl one -27- ------------- - ---------- installed ------, ΓΓ ------ line (know first read the notes on the back of the clean page and then write this page) wood paper ruler general trapped Xijiabei Zhun (CNS) A 4 present lattice (210 X 297 g; $) 81.9.20.000 V. Description of the invention () 4) A6 B6 1 monopyridyl) 5-fluoro-oxazoline and 3-ring Propyl-5-isoradonylmethyl 1, 2, 4_ gas two ms prepared; 3 — (3 — cyclopropyl 1, 2, 4 — gas diazo S—5—yl) one 5-(3, 3-dimethylmorpholinyl) -6-fluoroquinazoline [1, 5 a ° C, consisting of quinazoline 3, 3 quinazoline 2-ambient and 3- (compound 44), m. p. 2 (3, '3-dimethylmorpholine 4 4-2 4 6)-5 _ gas-cyclopropyl- 5 -iso- radonyl methyl 1, 2, 4-gas-4-di It is prepared by Qimao; (please read the notes on the back of Qizhi first, and then write the clothes page). -Cyclone and palladium 3 6 -gas-yl) oxazoline 3 -ring N-(-quinazol [1, 17 0-17 dimethylaminopropylpropyl 5-isopropyl-1, 2 , 4_mdifluoros 2 -dimethylaminoethyl) -N- [1, 5-a] quinazole (Combined 2t, composed of 2-amino-6-ethyl) -N-ethylaminoaminomethyl-1, 2,4--5_ group) monoethylamino) one substance 4 5), m cyanide -4-(N) -quinazoline and nitrodiazepines-3-(3-cyclopropyl-1, 2, 4 -gas diazepines 5-4, 5-dihydrogen 5-oxo squint Azole [1, 5-a] quinoline 6-atmosphere 3-(3-cyclopropyl-1 1> 2 4 oxydiazepine_5-yl)-5 -morpholine quinazole [1, 5-a 〕 A quinazoline (1. 45g) dissolved in 25ml of 6MM amic acid at 45K: mixed for 45 minutes, and then the mixture in a cold aqueous solution, but to 0 t: and over 28- This paper ruler and applicable China Four standard (CNS) A4 specifications (210 X 297 g; $) 81.9.20,000 Α6 Β6 V. Description of the invention (〗 Γ) Filter out the sediment > 2 5 m! Of water and 5 X 1 m 1 of ethyl acetate > finally washed with 10 m 1 of diethyl m > dried crystalline product > available title of 8 5 S ί dagger compound tm • P-2 7 0 — 2 7 2 V (decomposition) 〇 Prepare the following chemical in a similar manner Compound 3 — (5 — Cyclopropyl- 1 > 2 · > 4 monochlorodiazepine-2-yl)-6-fluoro-4 5 monodihydro- 5-gas-zonazo r 1 »5 — A] Leptozoline »m • P • 2 6 〇— 2 6 4 V (decomposed) by hydrolysis of 3 mono (5 — cyclopropyl — 1 f 2 1 4 oxodim — 3 monoyl) 6 — fluorine — 5 — (3 5 dimethylmorpholine) benzozole — r L 1 »5 aj quinazoline to get 1 3 — (5 — cyclopropyl — 1» 2 »4 — m diaza δ — 3 — Base) — 7 — gas — 4 5 — 2 — M 2 — 5 — gas — zonazo C 1 > 5 — a oxazoline »m P • 〇5 4 — 2 5 5 ♦ By hydrolysis 3 — (5 — ring Propyl 1 1 2 2 4 4 — Chlorodirym — 3 — yl) — 7 Monofluoro — 5 — (3 »2 dimethylmorpholine) Myrazole—— [1 t 5 1 a J Quinazoline And -------------------------- installed ------. 玎 ------ line < know first ^ back Zhi; ± Nianshi-'; * Hori Script 1) Printed by MS Industrial and Consumer Cooperatives, Central Bureau of Standards, Ministry of Tobacco and Economic Affairs ¾ Obtained; Example 4 5, 6-two gas one 3- (3-cyclopropyl one 1, 2, 4, 4- oxo two gas one five-yl) one azole [1, 5_a] quinazoline-IS mixing The mixture contains 6-atmosphere-3-(3-cyclopropyl-1, 2, 4-oxydikryl- 5-yl)-4, 5-dihydro-5-1-oxazolidine [1, 5 — A] Quinazoline (1. Og), tripropyl-29- This paper scale i4 uses the Chinese and Western Standards (CNS) A 4 present grid (210 X 297 public goods) 81.9.20,000 ΙΑιή ,. Α6 Β6 The Ministry of Economy, Central Standards Bureau, g-consumer cooperatives printed 5th generation V. Description of invention) Amine (〇 • 5 m 1) and oxygenation m (5 m 1) »Heated under 1 4 〇 一 1 5 0 〇1 After hours »Add P 0 C 1 2 (5 m 1) and tripropylamine (0 * 5 m 1)» and heat for 1 * 5 hours 9 and then pour this warm mixture into 2 0 0 m 1 in water 9 and vigorously mix 〇1 after 5 minutes > add 1 0 〇m 1 of dimethane > collect insoluble substances in the water »wash with diacetic acid 9 After drying, the title compound can be obtained after drying» its It is a yellow-brown crystal 〇m • P * 2 3 8-2 4 〇 »Yield 0 • 4 7 〇 prepared by the method like a cocoon. Prepare the following compound 5-atmosphere-3-(5-cyclopropyl-1 > 2 * 4 — Myristadi-3-yl) — 6 — m — myrazole C 1 »5 — a] — quinazoline» from 3 — (5 — cyclopropyl-1, 2 »4 diazo Mao-3-base)-6 — Gas — 4 > 5 — dihydro — 5 — gas-triazole C 1 »5 — a J quinazoline, 5 — atmosphere — 3 one (5 — cyclopropyl-1 > 2 > 4 — gas diazo S — 3 monoyl) — 7 — fluoro-zole [1 * 5 — a] — quinazoline »m» P * 2 4 9 — 2 5 1 t > from 〇 — (5 — Cyclopropyl — 1 y 2> 4 — oxydiazepine — 3 — yl) — 7 — fluoro — 4, 5 — dioxo — 5 — oxypyridazole Γ 1 9 5 — a 3 quinazoline Obtained Example 5 (R)-6-m-3-(3-cyclopropyl-1 > 2 t 4-m Dihemo-5-yl)-5-(2 monohydroxymethyl-1-at Alkyl) — quinazoline C 1 »5 a a quinazoline (compound 4 6) -30- (please read the notes on the back before writing a wooden page) This paper size and degree are suitable for Chinese and Western Jiafen Standard (CNS) Ψ 4 present grid (210 X 297 g: S) 81.9.20.000 A6 B6 V. Description of invention U1 ")) A mixture, including mg) and triethylamine 9), which is based on droplets (3-ring 1, 5 F (5 m filter anti-sleep mixed for 10 minutes to obtain the title 2 2 1 V with a similar 6 _ gas--group)-propyl one 1, —a〕 —quino 1) Suspension, leaching solution. After leaching the compound, its production is 0. Method of preparing 3- (3- 5 -thiomorphate 4 7), m · p (R) 2-hydroxymethylpyrrolidine (70 0 mg) Dissolved in anhydrous DMF (1ml added to a solution containing 5, 6-two atmospheres 3-2, 4-gas diazenium-5-yl)-zazolazoline (0.20s) dissolved in anhydrous DM liquid, ' The temperature is Ot :. After 20 minutes, the resulting crystalline product was diluted with 15 ml of water and mixed under Ot :, washed with water, and dried to become yellow crystals. m. p. 22 Ο-Ι 5 g. List of compounds: Cyclopropyl 1, 2, 4-gas two gas S_5 oxazoline [1, 5-a] oxazoline (Chem. 24 0-241C, from 5, 6-di atmosphere-3-) Anilazole 6 —Gas_ (3 —Cyclopropyl_1,2, 4 —Oxydioxolane-5-yl, 5 3- (3- ---------------- -------- Installed ------, ΤΓ ------ line (read the notes on the back of 汸 first, then fill out this page> a) Quinazoline and thiomorpholine Separately prepared by the Ministry of Economic Affairs Central Standards Bureau tH Industrial and Consumer Cooperatives Co., Ltd. Cyclopropyl-1, 2, 1-yl) -5— (cis-2,6-dimethyla) quinoline (Compound 48), m , 5 4 one gas two gas S porphyrinyl) -mizole. P. 2 3 6 -5 2 3 8, prepared from 5, 6-mit rr pent-death-6 dimethylmorpholine; 4 _ gas Bis-cis 2, bis-gas 3 — (3-cyclopropyl_1,2, yl) -quinazoline [1, 5 — a] quinazoline and (S) 6 — gas — 3 — (3 — ring Propyl 1,2,4 3 1 The scale of wood paper is in accordance with the Chinese and Western standards (CNS> A4 specifications (210 X 297 public goods). Oxygen 81.9.20,000 Printed by the Ministry of Economic Affairs Zhongjiabei Zhugongju Industrial Co., Ltd.% A6 B6 V. Description of the invention (Μ) Nitrogen-5-yl) -5 2 —Methylmethyl_1_pyrrolidine) quinazoline [1,5_a] quinazoline (Compound 49), mp 266 — 269 ° C, consisting of 5, 6 — diazo 3_ (3 — cyclopropane Based on 1,2,4-oxodioxamonoyl) monozole [1,5-a] quinazoline and (S) _2 —methoxymethylpyrrolidine; (S)-6 — 3-1-3 (3-cyclopropyl-1, 2, 4-oxodimethan-5-yl) -5- (2-rea-ylmethyl-1- (ft taryl)) benzoazole [1 . 5-a] Quinazoline (compound 50), m.P. 230 — 232t, consisting of 5, 6-dichloro- (3-cyclopropyl-1, 2, 4_ oxydioxa-5-yl) Li [1, 5-a] quinazoline and (s)-2-hydroxymethyl at pyrrolidine prepared; 6-m-3-(3_ cyclopropyl 1, 2, 4-chlorodicyanide Molo-5 yl) -5— (3-hydroxy-1-1-shodinyl) quinazoline [1, 5-a] quinazoline (compound 51), m.P. 258-261 from 5, 6-di Gas 3 — (3_photopropyl-1, 2, 4, — «diazepine-5-yl) -quinazole [1, 5—a] oxazoline and 3-hydroxy help pyridine prepared; 6— Chlorine-3 — (3-cyclopropyl one 1, 2, 4-chlorodiazepine S-5 monoyl) —5- (4-phenyl-1 1 pair of diazahexyl ring) -squinazole [1,5-a] siazolin (Compound 52), m. ρ · 255-2 57t :, from 5, 6-dihydrogen 3 — (3- cyclopropyl 1, 2, 4-gas diazonium S — 5 — yl) monoazole [1, 5 — a] Prepared by quinazoline and 1-phenyl-p-diazepine; -32-. The paper scale is applicable to the Chinese standard (CNS> A 4 present grid (210 X 297 mm) 81.9.20.000- ----------------------- installed ------ tr ------ line (please read the notes on the back of 汸 before filling in (This page)

C.M A6C.M A6

垤濟部中央標準尽負工消費合作社印焚 五、發明説明卜1) 6 —氛一 3— (3 — 環丙基一 1, 2, 4 —氧二氮 S- 5 —基)_5 — (4 一甲基一 1 一對二氮己環)一咪唑〔1 ,5 — a〕喹唑啉(化合物 53) , m. P. 273-2 7 2 t:,由 5, 6 —二氛一 3 - (3 -環丙基一 1, 2, 4一氣二氮茂一5—基)一眯唑〔1, 5—a〕喹唑啉和 1 -甲基對二氮己環製備而‘得; 6 —氣一 3 — (3 —環丙基—1, 2, 4 —氣二氣茂一5 一基)一 5_ (4 — (2 —羥基乙基)一1 一對二氮己環 基)-眯唑〔1, 5-a〕瘦唑啉(化合物54) , m . P . 252-254X:,由 5, 6 -二氛一3 - (3 -環 丙基一 1, 2, 4 -氣二氮茂一 5 —基)一眯唑〔1, 5 一a]喹唑啉和1一 (2—羥基乙基)對二氮己環啉製備 而得; 5 —胺基一 6 —氛一 3 — (3 —環丙基—1, 2, 4 —氧 二氮S — 5 —基)一眯唑〔1, 5 — a〕喹唑啉(化合物 55) , m . p . 343T;,由 5, 6 — 二氣一3— (3 一環丙基一1, 2, 4—氣二氮茂一5—基)一眯唑C1 ,5_a〕喹唑啉和銨水溶液裂備而得; 6 —氣一 3_ (3 — 環丙基一 1,2,4 一 氣二第 S—5 一基)一 5_ (4 —丙基一1_對二氮己環基)_眯唑〔 1, 5 — a〕#唑琳(化合物 56) , m. P. 186- 188t:,由 5, 6 -二氣一3 — (3 -環丙基一 1, 2 ,4一氣二氮茂一5-基)一眯唑〔1· 5—a〕喹唑啉 -3 3- 本纸張尺71通用taa家標準(CNS)甲4規格(210 X 297公;$ ) 81.9.20.000 ...........- Ι1ΓΙΙ I - . - «. ‘.'βτι,ι, . I,I .ϋ^ΐ||Ι||Ι·Ι|ΙΜ|ί·〇αΐν-4*1·>·)ί9**>ι'[ηΐϋ (II«·»·'"* - . .....\*β ulltl λ«-ι· -·' —a 外—< ------------------------装------tr------嫁 (請先閲汸背面之注*事項再塡寫本頁) 〆 / 9 · ,·^ΙΧύΌό Α6 Β6 五、發明説明) 經濟部中夹標準局員工消費合作社印« 和 1 一 丙 基 對 二 氮 己 環 製 備 而 得 i 3 — ( 5 — 環 丙 基 — 1 > 2 » 4 一 氧 二 氮 一 3 — 基 ) 一 6 — 氟 — 5 — 嗎 啉 基 — 眯 唑 r 1 » 5 — a 喹 唑 啉 ( 化 合 物 2 1 ) » m • P • 2 0 4 — 2 0 6 , 由 5 — 氣 — 3 — ( 5 環 丙 基 — 1 2 f 4 — m 二 氮 — 3 一 基 ) 一 6 一 氟 — 眯 唑 C 1 > 5 — a ] ®·唑 啉 和 嗎 啉 製 備 而 得 t 5 — ( N — 環 丙 基 甲 基 — Ν — 甲 基 胺 基 ) — 3 — ( 5 — 環 丙 基 — 1 » 2 繋 4 — 氣 二 氮 — 3 — 基 ) — rn — 氟 — 眯 唑 〔 1 > 5 一, a ] 喹 唑 啉 ( 化 合 物 5 7 ) » m • P • 1 7 6 — 1 7 7 t: > 由 5 — 氮 — 3 — ( 5 — 環 丙 基 一 1 » 2 > 4 — 氣 二 氮 S — 3 — 基 ) — 7 — Μ — 眯 唑 C 1 » 5 — a ] 喹 唑 啉 和 ( N 一 甲 基 胺 基 甲 基 ) 環 丙 烷 製 備 而 得 t 3 — ( 5 — 環 丙 基 — 1 » 2 * 4 — 氣 二 氣 S 一 3 一 基 ) — 7 — 氟 — 5 一 ( 3 — m 唑 院 基 ) — 眯 唑 [ 1 9 5 一 a > 喹 唑 啉 ( 化 合 饬 5 8 ) * m - P • 2 4 0 — 2 4 2 t: > 由 5 — 氛 — 3 — ( 5 — 環 丙 基 — 1 > 2 1 4 — 氧 二 m — 3 一 基 ) — 7 一 氟 — 咪 唑 Γ 1 1 5 — a ] 喹 唑 啉 和 噻 唑 院 製 備 而 得 * 3 — ( 5 一 環 丙 基 — 1 t 2 t 4 — 氧 二 氮 茂 — 3 — 基 ) 一 7 — 氟 — 5 — 嗎 啉 — 眯 唑 C 1 t 5 — a 喹 唑 啉 ( 化 合 物 5 9 ) » m • P • 2 1 3 — 2 1 4 t: > 由 7 — 氟 — 3 一 ( 5 — 環 丙 基 — 1 > 2 > 4 — m 二 氪 茂 一 3 — 基 ) — 5 一 氛 一 眯 唑 C 1 * 5 — a ] m 唑 啉 和 嗎 啉 啉 製 備 而 得 i -34- 本紙張尺·度適用中困國家櫺準(CNS>甲4现格(210 X 297公;S ) 81.9.20,000 ------------------------裝------ir------嫁<请先閲汸背面之;±念事項再塡寫本頁) 經濟部中兴標準局3工消"·合作社印焚 ^ X JL 0 ^ Α6 _Β6_ 五、發明説明(i丨) 3 - (5 —環丙基一 1, 2, 4 — 氧二氮S — 3 —基)一 5 - (1, 3 - 二噁烷一2 - 螺一 4’ —帮啶基)一 7 - 氟一眯唑〔1, 5 - a]喹唑啉(化合物60) , m . p .245 — 246¾,由 5 —氛一 3 - (5 — 環丙基一1 ,2, 4 —氣二氣茂一 3 —基)一7—氟一味哩〔1, 5 一 a]喹唑啉和1, 3 -二噁烷一 2 —螺一 4’ 一#啶製 備而得; 3 — (5 — 環丙基 _1, 2, 4 — 氧二氮 S— 3 —基)一 5 - (N — (2 —二甲基胺基乙基)一 N -甲基胺基)一 7 —氟—眯唑〔1, 5 — a〕嗤唑啉(化合物6 1) , m .p . 148 — 150^,由 5 -氛一3 - (5 -環丙基 一 1. 2, 4 — 氧二氮 S— 3 - 基)—7 — 氟-眯唑〔1 ,5 — a〕瘦唑啉和N, N , Ν’ 一二甲基乙烯二胺裂備 而得; 3 - (5 —環丙基一1, 2, 4 —氧二氮茂一 3 —基)— 6 -氟一 5 — (4 一甲基一 1-對二氮己環基)一眯唑〔 1, 5 — a]喹唑啉(化合物 62) , m . p . 2 7 4 - 276^,由 5 — 氛一 3 — (5 —環丙基一 1, 2, 4 — 氣二ms — 3 —基)—6 -氟一眯唑〔1, 5 - a]喹唑 啉和1 _甲基對二氮己環製備而得; 3 — (5 —環丙基一 1,2, 4 —氣二氮茂一 3 —基)一 6 —氟一 5 — (4 一 (2 —羥基乙基)一 1 一對二氮己環 基)一眯唑〔1, 5 — a〕喹唑啉(化合物63) , m . -35- (請先閲汸背面之注念事項再塡寫本頁) •装· 訂- •線. 本紙張尺双適用肀囲a家標準(CNS>甲4现格(210 X 297公3E ) 81.9.20,000 經濟邡中央標準局員工消費合作让印焚 2ϋ〇υ〇 Α6 Β6 五、發明説明(U) P 2 2 8 — 2 3 〇 t: > 由 5 — 氮 一 3 — ( 5 一 環 丙 基 — 1 » 2 > 4 — 氧 二 氮 m — 3 — 基 ) 一 6 — 氟 — 眯 唑 r L 1 > 5 — a j 喹 唑 啉 和 1 — ( 2 一 羥 基 乙 基 ) 對 二 氮 己 環 製 備 而 得 « 3 — ( 5 — 環 丙 基 — 1 > 2 » 4 — 氧 二 氮 S — 3 — 基 ) 一 7 — 氟 — 5 — ( N — ( 2 羥 基 乙 基 ) — N — 甲 基 胺 基 ) — 眯 唑 C 1 » 5 — a ] 喹 唑 啉 ( 化 合 物 6 4 ) » m • P • 1 6 1 — 1 6 3 X: > 由 5 — 氛 — 3 一 ( 5 — 環 丙 基 — 1 > 2 • 4 — m 二 氮 — 3 — 基 ) — 7 — 氣 — 咪 唑 C 1 » 5 — a J 喹 唑 啉 和 — ( N 一 甲 基 胺 基 ) 乙 醇 製 備 而 得 2 一 ( 5 — 環 丙 基 — 1 > 2 4 — 氯 二 S — 3 — 基 ) — 7 — 氰 — 5 — ( 4 一 m 哌 啶 基 ) — 眯 唑 C 1 ) 5 — a Ί 喹 唑 啉 ( 化 合 物 6 5 ) » m • P • 2 3 4 — 2 6 1C ( 分 解 ) * 由 5 — 氛 — 3 — ( 5 — 環 丙 基 一 1 > 2 » 4 — 氧 二 氣 茂 一 3 — 基 ) — 7 — 氟 - 咪 唑 r 1 * 5 — a ] 喹 唑 啉 和 4 — 啶 酮 裂 備 而 得 3 — ( 5 — m 丙 基 — 1 > 2 t 4 — 氯 二 氮 茂 — 3 — 基 ) — 7 一 氣 — 5 — ( N — 甲 基 — N — 1 — 甲 基 一 4 — 啶 基 ) 胺 基 ) — 眯 唑 r 1 f 5 — a 3 喹 唑 啉 ( 化 合 物 6 6 ) > m P • 2 0 4 — 2 0 7 » 由 5 — 氛 — 3 一 ( 5 — 環 丙 基 — 1 > 2 > 4 一 氣 二 氮 — 3 — 基 ) — 7 一 氟 一 眯 唑 1 > 5 一 a ] 喹 唑 啉 和 1 — 甲 基 一 4 — .( 甲 基 胺 基 ) 啶 製 備 而 得 1 -36- ------------------------装------.丌------^ (請先閲i$背面之注念事項再壜寫本頁) 本纸張尺度適用中困西家標準(CNS)甲4说格(210 X 297公:¾ ) 81.9.20,000 經濟部中喪標準局員工消费合作社印焚 Αβ _B6_ 五、發明説明(Μ ) 實例6 5_嗎啉一眯唑〔1, 5 - a]喹唑啉一 3_羧醛胺 一}«拌的混合物,包括乙基5 —嗎啉一眯唑〔1, 5 一 a〕唼唑啉一3 —羧酸酯(2. Og)和乙鏗胺(1. 2g)溶於20ml的無水二甲基甲醒胺中,將其在80 t:加熱,加入3 0 %之溶於·甲醇(1 m 1 )的甲氣化納溶 液及趄纓》拌此混合物2小時,溫度為100t:。冷却至 室溫及以異丙醇(20ml)稀釋,過濂出結晶物,以異 丙酵(15ml),水(20ml)和二乙醚(10ml )洗灌,乾燥後可得黃色结晶狀的標題化合物,m . p . >300^0,産率 1. 3g。 實例7 3 - m基一 5 —暍啉一味唑〔1,5 — a]喹唑啉(化合 拗6 7 ) 以液滴的方式将漠(0 . 15ml)加至一含有三苯 基睽(0 . 8 g )溶於1 5 m丨甲撐氱化物的溶液中,溫 度為將一瞟啉—眯唑〔1, 5 — a〕#唑啉一 3 — 羧醯胺(0. 5g)和三乙胺(0. 83mi)加入此溶 液中,在室溫下魇拌此结果反睡混合锪3小時,然後於寘 空中蒸發。加入醋酸乙酯(1 0 m 1 )於殘留拽中,然後 過濾分離出粗结晶標題化合挠。將乾燥結晶物溶解於丙酮 (30ml),且加入過量之溶於二乙醚中的氛化氫以分 離搮題化合物的氩氛化物,其為be i ge的結晶物。Μ -3 7- 本纸張尺及通用中因a家標準(CNS)甲4规格(210 X 297公货) 81.9.20,000 ------------------------裝------.玎------^ (請先閲-背面之注念事項再塡寫本頁) A6Printed by the Central Standards Ministry of Economic Affairs, Consumer Cooperatives, and the Fifth, Invention Note 1) 6 — Atmosphere 3 — (3 — Cyclopropyl 1, 2, 4 — oxydiazepine S-5 — base) _5 — ( 4 monomethyl-1 1 pair of diazacyclo) -imidazole [1,5-a] quinazoline (compound 53), m.P. 273-2 7 2 t :, from 5, 6-dihydrogen 3-(3-cyclopropyl-1,2,4-nitrogenazo-5--yl) -quinazoline [1, 5-a] quinazoline and 1-methyl-p-diazepine are prepared; 6 —Gas 3 — (3 —Cyclopropyl—1, 2, 4 —Gas dichloromethane—5 monoyl) —5_ (4 — (2-hydroxyethyl) —1 pair of diazahexyl)- Pyrazole [1, 5-a] Leptozoline (Compound 54), m.P. 252-254X :, from 5, 6-diamine-3-(3-cyclopropyl-1, 2, 4--gas Diazono-5-yl) -quinazoline [1,5-a] quinazoline and 1- (2-hydroxyethyl) -p-diazepine; prepared from 5-amino-6-ambient-3 — (3-cyclopropyl-1, 2, 4-oxodiazepine S-5-yl) quinazoline [1, 5-a] quinazoline (compound 55), m.p. 343T ;, by 5 , 6 — two gas one 3 — 3 Monocyclopropyl-1, 2, 4-gas diazenium-5-yl) quinazoline C1, 5_a] quinazoline and ammonium aqueous solution are prepared by cracking; 6 —gas 3_ (3 — cyclopropyl-1 , 2,4 one gas two S-5 monoyl) 5_ (4-propyl-1-pyrazine ring) _ 眯 azole [1, 5-a] #zoline (compound 56), m. P. 186-188t :, consisting of 5, 6-difluoro-3- (3-cyclopropyl-1, 2, 2, 4-dinitrogeno-5-yl) -quinazoline [1.5-a] quinazoline -3 3- This paper ruler 71 universal taa standard (CNS) A 4 specifications (210 X 297 male; $) 81.9.20.000 .........- Ι1ΓΙΙ I-.-«. ' .'βτι, ι,. I, I .ϋ ^ ΐ || Ι || Ι · Ι | ΙΜ | ί · 〇αlν-4 * 1 · > ·) ί9 ** > ι '[ηΐϋ (II « · »· '&Quot; *-. ..... \ * β ulltl λ« -ι ·-·' —a 外 — < ------------------ ------ Pretend ------ tr ------ Marry (please read the note on the back of the 汸 first and then write this page) 〆 / 9 ·, ^ ΙΧύΌό Α6 Β6 V. Invention Explanatory Note: The employee consumer cooperative of the China Bureau of Standards, Ministry of Economic Affairs, prints «and a 1-propyl p-diazepine prepared from i 3 — (5 — cyclopropyl — 1 & g t; 2 »4 oxodiazin-3-yl)-6-fluoro-5-morpholinyl-zonazo r 1» 5-a quinazoline (compound 2 1) »m • P • 2 0 4 — 2 0 6, consisting of 5 — gas — 3 — (5 cyclopropyl — 1 2 f 4 — m diazepine — 3 monoyl) — 6 monofluoro — zonazo C 1 > 5 — a] ® · oxazoline and Preparation of morpholine yields t 5 — (N — cyclopropylmethyl — Ν — methylamino) — 3 — (5 — cyclopropyl — 1 »2 series 4 — gas diazide — 3 — group) — rn — Fluorine-Fenazole [1 > 5 a, a] Quinazoline (compound 5 7) »m • P • 1 7 6 — 1 7 7 t: > from 5 — nitrogen — 3 — (5 — cyclopropyl Radical 1 »2 > 4 — gas diazonium S — 3 — yl) — 7 — Μ — benzozole C 1» 5 — a] quinazoline and (N-methylaminomethyl) cyclopropane To get t 3 — (5 — cyclopropyl — 1 »2 * 4 — gas two gas S — 3 — 1) — 7 — fluoro — 5 — (3 — m oxazolyl) — zonazo [1 9 5 1a> Quinazoline (Synthetic Compound 5 8) * m-P • 2 4 0 — 2 4 2 t: > from 5 — atmosphere — 3 — (5 — cyclopropyl — 1 > 2 1 4 — oxodiane m — 3 monoyl) — 7 monofluoro-imidazole Γ 1 1 5 — a] quinazoline and thiazole prepared from * 3 — (5 monocyclopropyl — 1 t 2 t 4 — oxydiazepine — 3 — Radical) — 7 — fluoro — 5 — morpholine — myrazole C 1 t 5 — a quinazoline (compound 5 9) »m • P • 2 1 3 — 2 1 4 t: > from 7 — fluoro — 3 One (5 — cyclopropyl — 1 > 2 > 4 — m dikryptomene — 3 — yl) — 5 is prepared from an oxazolidine C 1 * 5 — a] m oxazoline and morpholine to give i- 34- The size and degree of this paper are applicable to the standards of the middle and poor countries (CNS > A4 present grid (210 X 297 g; S) 81.9.20,000 ------------------- ----- Pretend ------ ir ------ marry < Please read the back of the 汸 first; ± read the matter and then write this page) ZTE Standardization Bureau of the Ministry of Economic Affairs 3Work Consumer Yin Fen ^ X JL 0 ^ Α6 _Β6_ V. Description of the invention (i 丨) 3-(5 —cyclopropyl 1, 2, 4 — oxydiazepine S — 3 —yl)-5-(1, 3 -dioxane- 2 -spiro-4′-pyridinyl)-7 -fluoro-pyrazole [1, 5- a] Quinazoline (compound 60), m.p. 245-246¾, consisting of 5-ambient 3- (5-cyclopropyl-1,2,4-pyridine-3-yl) -7-fluoro Yiweili [1, 5-a] quinazoline and 1, 3-dioxane- 2 —spiro-4 ′-# prepared from pyridine; 3 — (5 — cyclopropyl_1, 2, 4 — oxygen Diazo S 3 -yl)-5-(N — (2-dimethylaminoethyl) -N-methylamino) -7-fluoro-quinazol [1, 5-a] oxazoline (Compound 6 1), m.p. 148 — 150 ^, consisting of 5-Amino 3-(5 -cyclopropyl 1, 2, 4-oxydiazepine S 3 -yl)-7-Fluorine Azole [1,5—a] Leptazoline and N, N, Ν′-dimethylethylenediamine are prepared by cracking; 3-(5-cyclopropyl-1, 2, 4-oxodiazepine-3 — Group) — 6-fluoro-5- (4-methyl-1-p-diazepine) quinazoline [1, 5-a] quinazoline (compound 62), m. P. 2 7 4 -276 ^, from 5 — atmosphere one 3 — (5 —cyclopropyl one 1, 2, 4 — gas di ms — 3 —yl) —6-fluorofluoroquinazoline [1, 5-a] quinazoline and 1_methyl-p-diazepine are prepared; 3 — (5-cyclopropane A 1,2, 4-gas diazepine-3-yl)-6-fluoro-5-(4 one (2- hydroxyethyl)-1 a pair of diazohexyl)-azoazole [1, 5 — A] Quinazoline (compound 63), m. -35- (please read the notes on the back of 汸 before writing this page) • Installation · Order-• Line. This paper ruler is applicable to 囀 囲 a house standard (CNS > A 4 present grid (210 X 297 public 3E) 81.9.20,000 Employee consumption cooperation of the Central Bureau of Economics and Politics for printing and burning 2 ϋ〇υ〇Α6 Β6 V. Description of invention (U) P 2 2 8 — 2 3 〇t : ≫ from 5 — nitrogen 3 — (5 monocyclopropyl — 1 »2 > 4 — oxydiazepine m — 3 — yl) 6 — fluoro — zonazo r L 1 > 5 — aj quinazoline And 1 — (2 monohydroxyethyl) p-diazepine ring to prepare «3 — (5 — cyclopropyl — 1 > 2» 4 — oxydiazepine S — 3 — yl) — 7 — fluorine — 5 — (N — (2 hydroxy Group) — N — methylamino group) — zonazole C 1 »5 — a] quinazoline (compound 6 4)» m • P • 1 6 1 — 1 6 3 X: > from 5 — atmosphere — 3 One (5 — cyclopropyl — 1 > 2 • 4 — m diazo — 3 — group) — 7 — gas — imidazole C 1 »5 — a J quinazoline and — (N-methylamino) ethanol Prepared to give 2- (5-cyclopropyl-1> 2 4 — chlorodi S — 3 — yl) — 7 — cyano — 5 — (4-m piperidinyl) — quinazole C 1) 5 — a Ί quinazoline (compound 6 5) »m • P • 2 3 4 — 2 6 1C (decomposition) * from 5 — atmosphere — 3 — (5 — cyclopropyl-1 1> 2» 4 — oxydioxa 3 — yl) — 7 — fluoro-imidazole r 1 * 5 — a] Quinazoline and 4-pyridone are prepared by cracking to obtain 3 — (5 — m propyl — 1 > 2 t 4 — chlorodiazepine — 3 — yl) — 7 one gas — 5 — (N — methyl — N — 1 — methyl-4-pyridyl) amine) — zonazo r 1 f 5 — a 3 quino Porphyrin (compound 6 6) > m P • 2 0 4 — 2 0 7 »from 5 — atmosphere — 3 one (5 — cyclopropyl — 1 > 2 > 4 mononitrogen — 3 — group) — 7 1-fluoro-zirconium 1 > 5-a] Quinazoline and 1-methyl-4-((methylamino) pyridine prepared from 1-36- ------------ ------------ installed ------. 丌 ------ ^ (Please read the notes on the back of i $ before writing this page) This paper size is applicable Western Standard (CNS) A 4 Said (210 X 297 g: ¾) 81.9.20,000 Printing and Burning Αβ _B6_ of the Consumers ’Bureau of the Ministry of Economic Affairs of the Ministry of Economic Affairs Αβ _B6_ V. Description of Invention (Μ) Example 6 5_Morpholine 1 [2,5-a] quinazoline 3_carboxaldehyde amine «mixed mixture, including ethyl 5-morpholine-triazole [1, 5 a] oxazoline 3-carboxylic acid Ester (2.0 g) and ethyiamine (1.2 g) were dissolved in 20 ml of anhydrous dimethylformamide, heated at 80 t: added 30% dissolved in methanol (1 m 1) The solution of sodium methoxide and fusidium was mixed with this mixture for 2 hours at a temperature of 100t. Cool to room temperature and dilute with isopropanol (20ml). After leaching out the crystals, rinse with isopropanol (15ml), water (20ml) and diethyl ether (10ml). After drying, you can obtain the title of yellow crystal The compound, m.p.> 300 ^ 0, yield 1. 3g. Example 7 3-m-based 5- 5-chrysoline-monozole [1,5-a] quinazoline (combined 拗 6 7) in the form of droplets of desert (0.15ml) added to a triphenyl-containing compound ( 0. 8 g) dissolved in a solution of 15 m 丨 methylene chloride, the temperature is to be a porphyrin-zonazo [1, 5-a] #zoline-3-carboxamide (0.5g) and Triethylamine (0.83 mi) was added to this solution, and the results were mixed at room temperature for 3 hours, and then evaporated in the air. Ethyl acetate (10 m 1) was added to the residue, and then the crude crystals were separated by filtration. The dried crystalline material was dissolved in acetone (30 ml), and an excess of hydrogenated atmosphere dissolved in diethyl ether was added to separate the argon chlorinated compound of the title compound, which was a crystal of beige. Μ -3 7- This paper ruler and the common standard (CNS) A4 specifications (210 X 297 public goods) 81.9.20,000 ------------------ ------ install ------. 玎 ------ ^ (please read first-the notes on the back and then write this page) A6

五、發明説明(W) {埼先閲讀背面之注念事項再壜寫衣頁) .Ρ· 225—223t,産率〇· 3g。 以類似的方法裂備下列化合物: 3 —氡基一8 -甲氧基一 5 -嗎啉基一眯唑〔1, 5 - a 〕喹唑啉(化合物 68) , m . p. 283-284 r, 由甲氧基一5—媽啉一眯唑〔1, 5-a]曈唑啉一 3 _羧.醛胺裂備而得。 實例8 5 —嗎啉一眯唑〔1, 5_a〕喹唑啉一 3 —羧醯胺肟 一混合物,包含氳氣化鈉(〇. 〇6g),羥基胺氳 氛化物(0. 10g)和甲醇(3ml),将其在室溫下 «拌1小時。理由過濾分離出羥基胺.其為甲酵溶液.以 甲醇(7m丨)洗灌濾餅。加入羥基胺溶液至一包含有3 —氰基一 5 -嗎啉一味唑〔1,5 — a]喹唑啉(0. 1 6 g)溶於5m 1的甲醇懸浮液中。迺流反應混合物4小 時,冷却至室溫及將其過濾。以甲醇洗灌結晶産物,乾燥 後可得標題化合物,其為黃色的結晶物,m. p . 212 -213TC,産率 〇. 17g。 簧例9 經濟部中央標準烏S工消費合作社印5代 5 —嗎啉一 3 — (5 -三氰甲基-1, 2,4 一氧二氮茂 一 3 —基)一眯唑〔1, 5 - a〕氆唑啉(化合物69) 以液滴的方式加入三氟乙酸酑(〇. 15ml)至一 包含5—嗎啉一眯唑〔1, 5-a〕喹唑啉_3_羧醯胺 肟溶於4m1無水四氫呋喃的懸浮液中,在室溫下擻拌3 -38" 81.9.20,000 本纸張尺度適用+國Η家標準(CNS>乎4现格(210 X 297公釐) A6 B6 η» ^ 五、發明説明(5Γ) (請先閲讀背面之注念事項再壜寫本頁) 小時浚,於奠空中蒸發反應混合物。將殘留物溶解於水和 醋酸乙酯的混合拽中。以水洗濯有機相層,及以無水硫酸 镁乾燥且蒸發至乾。將結晶物S拌於異丙醇(3ml)中 洗灌,可得黃色標題结晶化合物,m. p. 182-18 6力,産率0. 06g。 實例1 0 3 — (5 —環丙基一 1, 2, 4 —氣二氮茂一 3 —基)一 6-甲氧基一 5 —嗎啉一眯唑〔1, 5 — a〕喹唑啉(化 合物7 0 ) 一混合物,包含有6 —甲氧基一 5 —嗎啉一咪唑〔1 .5 - a〕喹唑啉一 3 —羧酵胺肟(0· 9g),乙基環 丙基羧酸酯(1. 7g),分子篩(3g),和80%的 Μ化納(0.lg)溶於20ml的無水DMF中,将其 在1 2 0 t加熱1 . 5小時,冷却混合物至室溫,以醑酸 (0. 5ml)及甲撐氛化掬(20ml)稀稞,且將其 過濾。蒸發過濾過的混合物且以管柱層析法(HPLC) 纯化(洗提劑:甲撐氛化物:丙酮(2: 1)),可得黃 色結晶狀的標題化合物,m. p. 227—228t,産 經濟郐中央標準局員工消費合作社印焚 率〇.3 8 g。 以類似的方法製備下列化合物= 3 — (5_ (1 —甲基環丙基)一1, 2, 4 —氣二氮茂 一 3 —基)一 5 —嗎啉一眯唑〔1,5 — a〕一喹唑啉( 化合物71) . m. p . 232 — 236它,由5 —嗎啉 -39- 81.9.20.000 本紙張尺度適用t國a家標準(CNS)子4規格(210 X 297公货) U如 A6 _B6_ 五、發明説明(砘) (諳先閲汸背面之:iis事項再塡寫本頁) 一眯唑一 〔1,5 — a〕€唑啉一 3 -羧酵胺肟和乙基1 一甲基環丙基羧酸酯製備而得。 實例1 1 3 - (3 —環丙基—1, 2, 4 -氯二氮茂一5 —基)一 5— (1一氧一硫代嗎啉)一咪唑〔1, 5-a]喹唑咐 (化合物7 2 )和 3— (3 — 環丙基一 1, 2, 4_m 二氮茂 一 5 — 基)一 5 - (1—二氧一硫代瞟啉)一眯唑〔1, 5 — a〕喔睡 啉(化合物7 3 ) 一溶液,包含有3 — (3 —環丙基一1, 2, 4 —氣 二氮S — 5 -基)-5 —硫代嗎啉一眯唑〔1, 5 — a] 喹唑啉(0· 5g)和30%之過氛化氳水溶液(0. 2 ml)溶於15ml的醋酸中,將其在迺流40分莆。在 冷却至室溫後,過濾出3 — (3 —環丙基一 1, 2, 4 — 氣二氮S—5—基)一5— (1,1一二氧一硫代嗎啉) 一眯唑〔1, 5-a〕喹唑啉的粗結晶産物,由DMF中 再结晶可得纯産物,Μ. P. 328—335f,産率6 4 m g 〇 經濟部中央標準工消費合作社印« 過逋過的醋酸在稟空中蒸發,殘留物用水《拌(10 ml),過濾可得3 — (3 —環丙基一1, 2 —4_氧二 SS — 5 —基)_5 - (1 一氧一硫代嗎啉)_眯唑〔1 ,5 — a〕喹唑啉結晶粗産拽,由DMF中再結晶可得純 化合物,Μ. p . 293 — 294t:,産率 0. 2s。 -40- 81.9.20.000 本紙张尺度通用t國西家標準(CNS〉肀4现格(210 X 297公釐) “如, A6 ^_ 五、發明説明(彳q) (清先閲汸背面之注念事項再填寫本頁) 霣例1 2 7 — 氟—3 - (3 - 異丙基一1, 2, 4— 氧二氣 S— 5 一基)—5 —嗎啉一眯唑〔1, 5 — a〕喹唑啉(化合物 7 4) 一混合物,包含有乙基7 —氟一 5 —嗎啉一眯唑〔1 ,5-a]喹唑啉-3-矮’酸酯(1. 6g) . 2 -甲基 一 1_丙烷羧趣胺肟(2. 4g),粉碎4A分子篩(3 .5 g ),和氫化納(0 . 1 4 g , 8 0 %溶於礦物油中 )溶於20ml的無水DMF中,在室溫下》拌,.一小時 浚再加入羧鏗按肟(2 . 4 g )和氫化鈉懸浮液(0 . 1 4 g ) , ϋ缠邋拌此混合物1小時,加入冰醋酸(2ml )和二氛甲烷(50ml)。在沈游物溶解後.經由矽藻_ 土過濾分子篩。蒸發濾液,殘留物用100m1的水研磨 ,過濾收集未溶解的部份,乾燥及以2 5ml的丙酮處理 。過逋出黃色的結晶産物且將其乾燥,産率〇. 47g, m . p. 262-264t:〇 經濟部中央標準局WK工消費合作社印焚 -41- 本纸張尺及通用中困a家標準(CNS)甲4規格<210 X 297公:$ ) 81.9.20,0005. Description of the invention (W) {Sait first read the notes on the back and then write the clothing page). Ρ · 225-223t, yield 0.3g. Prepare the following compounds in a similar manner: 3- radon-8-methoxy-5-morpholinyl-quinazoline [1,5-a] quinazoline (compound 68), m.p. 283-284 r, Derived from the cracking of methoxy-5-mazoline quinazoline [1, 5-a] oxazoline 3_carboxy. Aldamine. Example 8 5-Morpholine quinazoline [1, 5_a] quinazoline -3-carboxamide oxime a mixture, including sodium gas vapor (0.06g), hydroxylamine radium odorate (0.10g) and Methanol (3ml), which was stirred at room temperature for 1 hour. The reason is that the hydroxylamine is separated by filtration. It is a formazan solution. The filter cake is washed with methanol (7m 丨). Hydroxylamine solution was added to a suspension containing 3-cyano-5-morpholine monozole [1,5-a] quinazoline (0.16 g) dissolved in 5 ml of methanol. The reaction mixture was flowed for 4 hours, cooled to room temperature and filtered. The crystalline product was rinsed with methanol and dried to give the title compound as yellow crystals, m.p. 212-213TC, yield 0.17g. Spring Example 9 Central Standard Wu S Industry and Consumer Cooperative of the Ministry of Economic Affairs of the Republic of India 5th generation 5-morpholine 3- (5-tricyanomethyl-1, 2,4 oxydiazepine-3-yl) -pyrazole [1, 5-a] Pyrazoline (Compound 69) Trifluoroacetic acid (0.15 ml) was added in the form of droplets to a mixture containing 5-morpholine-quinazoline [1, 5-a] quinazoline_3_carboxy Amidoxime is dissolved in a suspension of 4m1 of anhydrous tetrahydrofuran and stirred at room temperature for 3 -38 " 81.9.20,000. The paper size is applicable + National Standards (CNS > almost 4 grids (210 X 297 mm) A6 B6 η »^ V. Description of the invention (5Γ) (Please read the notes on the back before writing this page) Hun Jun, evaporate the reaction mixture in the air. Dissolve the residue in the mixture of water and ethyl acetate Medium. The organic phase layer was washed with water, dried over anhydrous magnesium sulfate and evaporated to dryness. The crystal S was mixed with isopropanol (3ml) and washed to give a yellow title crystalline compound, mp 182-18 Yield 0.06g. Example 1 0 3-(5-Cyclopropyl 1, 2, 4-gas diazenium 3-yl)-6-methoxy-5-morpholine-azole [1, 5 — A〕 Quinazole (Compound 70) A mixture containing 6-methoxy-5-morpholine-imidazole [1.5-a] quinazoline-3-carboxylamide oxime (0.9g), ethylcyclopropyl Carboxylic acid ester (1.7 g), molecular sieve (3 g), and 80% Mn (0.1 g) were dissolved in 20 ml of anhydrous DMF, which was heated at 120 t for 1.5 hours, and the mixture was cooled to At room temperature, dilute barley (20 ml) with acetic acid (0.5 ml) and formazan, and filter it. The filtered mixture was evaporated and purified by column chromatography (HPLC) (eluent: A Supporting compound: acetone (2: 1)), the title compound can be obtained as yellow crystals, mp 227-228t, the production and consumption rate of the Employees ’Cooperative of the Central Bureau of Standards and Economics, 0.38 g. The following method is prepared in a similar manner Compound = 3 — (5 — (1 —methylcyclopropyl) — 1, 2, 4 — gas diazenium-3-yl) — 5 — morpholine quinazoline [1, 5-a] quinazoline ( Compound 71). M. P. 232-236 It is composed of 5-morpholine-39- 81.9.20.000. The paper size is applicable to the national standard (CNS) sub 4 specifications (210 X 297 public goods) U such as A6 _B6_ Fifth, the description of the invention (砘) Face to face: iis matter and then write this page) Izozole [1,5-a] € oxazoline 3-carboxylamide oxime and ethyl 1-methylcyclopropyl carboxylate are prepared. Examples 1 1 3-(3-cyclopropyl-1, 2, 4-chlorodiazino-5-yl)-5-(1-oxo-thiomorpholine) monoimidazole [1, 5-a] quinazol (Compound 7 2) and 3- (3-cyclopropyl-1, 2, 4_m diazenium-5-yl)-5-(1-dioxathiothiophenoline) -mazole [1, 5-a 〕 Oxamorphine (compound 7 3) a solution containing 3- (3-cyclopropyl 1, 2, 4-gas diazo S-5-yl)-5-thiomorpholine-myrazole [1 , 5 — a] Quinazoline (0.5g) and 30% aqueous solution (0.2 ml) of over-aerosolized radium were dissolved in 15ml of acetic acid, and it was allowed to flow for 40 minutes. After cooling to room temperature, filter out 3- (3-cyclopropyl-1,2,4-gas diazo S-5-yl) -5- (1,1-dioxo-thiomorpholine)- The crude crystalline product of quinazoline [1, 5-a] quinazoline can be recrystallized from DMF to obtain a pure product, M.P. 328-335f, with a yield of 64 mg. Printed by the Ministry of Economic Affairs Central Standard Industry and Consumer Cooperative Society « The acetic acid that has passed through evaporates in the air, and the residue is mixed with water (10 ml) and filtered to obtain 3- (3-cyclopropyl-1,2-4-oxo-SS-5-yl) _5-(1 1oxy-thiomorpholine) _ quinazoline [1,5-a] quinazoline crystal crude product, recrystallized from DMF to obtain a pure compound, M. p. 293-294t :, yield 0.2s . -40- 81.9.20.000 The size of this paper is universal t Guo Xijia standard (CNS> Yu 4 present grid (210 X 297 mm) "For example, A6 ^ _ V. Description of invention (彳 q) Matters needing attention and then fill out this page) 霣 例 1 2 7 — Fluoro-3-(3-Isopropyl 1, 2, 4-Oxygen Dioxide S-5 Monoyl)-5-Morpholine-Mizole [1 , 5-a] Quinazoline (Compound 7 4) A mixture containing ethyl 7-fluoro-5-morpholine-quinazoline [1,5-a] quinazoline-3-dwarf acid ester (1 6g). 2-Methyl-1-propane carboxylamine oxime (2.4g), crushed 4A molecular sieve (3.5g), and sodium hydride (0.14g, 80% dissolved in mineral oil ) Dissolve in 20ml of anhydrous DMF and mix at room temperature. After one hour of dredging, add carboxyl oxime (2.4 g) and sodium hydride suspension (0.1 4 g). The mixture was added for 1 hour, and glacial acetic acid (2ml) and dichloromethane (50ml) were added. After the sediment was dissolved. The molecular sieve was filtered through diatomite. The filtrate was evaporated, and the residue was ground with 100m1 of water, and the undissolved part was collected by filtration. Portion, dried and treated with 25 ml of acetone. The yellow crystalline product is obtained and the Drying, yield 0.47g, m.p. 262-264t: 〇Printing and Burning-41 of the Central Bureau of Standards of the Ministry of Economic Affairs, WK Industrial and Consumer Cooperatives-41- This paper ruler and the general trapped a home standard (CNS) A 4 specifications < 210 X 297 public: $) 81.9.20,000

Claims (1)

六、申請專利範圍 A7 B7 C7 Γ: D7 f: .—種具有式.I的咪唑喹唑啉化合物6. Patent application scope A7 B7 C7 Γ: D7 f:.-An imidazoline compound of formula I 和藥物上可接受的酸加成鹽或其水合物,其中Q是 〇-?fAnd pharmaceutically acceptable acid addition salts or hydrates, where Q is 〇-? F ίί-0// ο ~ιτ Μ-Ο (請先閱讀背面之注意事項再塥寫本頁)ίί-0 // ο ~ ιτ Μ-Ο (Please read the notes on the back before writing this page) -C.QOR8 或-CN ; 其中R1是氫,直鐽或支鐽的烷基,未經取代的 或C! _s烷基取代的C3 _7環烷基,Ci 烷氣基 ,C! 烷氣基一Ci _s _烷基或三氬甲基;R8是 ®濟部中去梂準局KC工消&lt;k合忭社印ί我 C - 3 院氯其 以代 R S 烷一 的 取和· I I 或 性基 ζ 1 e 基 擇苯 R C I 烷 還 -或 ,1 S -基 ,基 C _ 基胺基烷 ,1 烷基啶基基 C S 烷呢羥烷 | 1 I 的 s e 基 1 S 代 一 i 韹 基 C | 取 1 1 曱 烷 , 1 基 c C , lffic 烷 ,一基 6 是 一 e 基基烷 I 別二 I 烷氧一 1 分 ,1 璟烷 S C 2 基 c 7 s I 的 R 烷以 | -缝和環的 3 1C 支 2 .1 性 c C I 或 R 7 擇是 ,基 S 別基羰 直 η 或分氣基 本九又家(CNS)甲·ί HA (2U) X 二、父) ,f \ 六、申請專利範圍 環或非環縮銅,或R2及R3和氮原子形成一 4 一 6値原 子的環胺基,在該環中条统中,一値或多傾碩原子可和氮 ,氣,硫,亞磺藍基,磺匿基或羰基所交換,或為其水合 物,一非環或環狀縮酮,這些環条統的每一値可選擇性被 一値或多値Ci _6烷基,Ci _6烷氧基一甲基,羥基 ,Ci+S —羥基烷基或苯基所取代。 R 4 , R 5 , Rs分別是氫,羥基,Cl, Br, F ,I ,三氟甲基,硝基,胺基,氮基,直鐽或支鐽C! _ s烷基,c2 烯烴基,C2 _6 -炔烴基,Ci _6 院氣基,C 1 _ S @氣基_〇1 _ s院基或C 1 _ s —院 氣基羰基; 其限制條件為當Q是 (诗先閲«背面之注意事項再項寫本頁)-C.QOR8 or -CN; where R1 is hydrogen, straight or branched alkyl, unsubstituted or C! _S alkyl substituted C3 _7 cycloalkyl, Ci alkane, C! Alkane One Ci _s _ alkyl group or triargyl methyl group; R8 is the Ministry of Economic Affairs of the Ministry of Economic Affairs KC Gongxiao &<; K He Yi She printed ー I C-3 Institute Chlorine instead of RS Alkanes and II Or sex group ζ 1 e group selected benzene RCI alkane-or, 1 S-group, the group C _ aminoamino alkane, 1 alkyl pyridyl group CS alkane oxane | 1 I of the se group 1 S generation-i Esteryl C | Take 1 1 methane, 1 group c C, lffic alkane, one group 6 is an e group alkyl group I other two I alkoxy one point, 1 squalane SC 2 group c 7 s I R alkane With |-slit and ring 3 1C branch 2.1 sex c CI or R 7 is selected, the base S other group carbonyl straight η or gas distribution basic Jiu Youjia (CNS) A · ί HA (2U) X Second, the father ), F \ Six, the scope of patent application ring or non-cyclic copper condensate, or R2 and R3 and the nitrogen atom to form a 4-6 6 atom cyclic amine group, in the ring system, one or more tilted atoms Can be exchanged with nitrogen, gas, sulfur, sulfinyl, sulfonyl or carbonyl, or its hydrate , A non-cyclic or cyclic ketal, each value of these ring systems can be selectively one or more values Ci _6 alkyl, Ci _6 alkoxy monomethyl, hydroxy, Ci + S-hydroxyalkyl Or substituted by phenyl. R 4, R 5, Rs are hydrogen, hydroxy, Cl, Br, F, I, trifluoromethyl, nitro, amine, nitrogen, straight or branched C! _ S alkyl, c2 alkenyl , C2 _6 -alkynyl group, Ci _6 yard gas group, C 1 _ S @ 气 基 _〇1 _ s yard group or C 1 _ s-yard gas group carbonyl group; the restriction is that when Q is (Poetry first reading « (Notes on the back will write this page again) 烴濟部中央揉準局Μ:工消«·合作社印5; 環 I 代 5 7 3 取一 I cg氮 3 ,未| C 基 一 6 的氯成基 氫代烷形乙 為取 i 3 是 能经 e R 不 不未 I eg 物 時 或 -R 合 同基 c N 化 7 烷丨,:|或1 R 6 Η 基 式 , I 是烷此 6 1 別 I 且 RW 分 S ’ I 3 |啦 5 H R 1 嗎 R 是和 C 代 • , 2 或硫 4 1 R 基或 R R ., 烷啉 , 中基 環嗎 時其烷 7 的 (CN?) τ7 4 CIO X :;·7 ν ) ATb3 B7 C7 D7 六、申請專利範圍 一嗎啉一眯唑〔1,5 — a〕唼唑啉一 3 —羧酸酯或6 氛一 3 - (3 —環丙基一 1,2,4 一嚼唑一 5 —基) 5 —嗎啉一畴唑〔1, 5 - a〕唑陛咐。 2.如申請專利範圍第1項之化合物,其中Q是 焓Central Ministry of Hydrocarbon Economy M: Work Consumers «· Cooperative Society Seal 5; Ring I Generation 5 7 3 Take an I cg nitrogen 3, not | C base a 6 chloro-based hydrogen alkyl form B is taken i 3 Yes It can pass e R but not without I eg or -R contract group c N 7 alkane 丨,: | or 1 R 6 Η basic formula, I is alkane 6 1 different I and RW points S 'I 3 | 5 HR 1? R is with C generation, 2 or sulfur 4 1 R group or RR., Alkanoline, in the middle of the ring is its alkane 7 (CN?) Τ7 4 CIO X:; · 7 ν) ATb3 B7 C7 D7 Six. The scope of patent application-morpholine-triazole [1,5-a] oxazoline 3-carboxylate or 6 atmosphere of 3- (3-cyclopropyl-1,2,4-pyrazole A 5-base) 5-morpholine-domain azole [1, 5-a] azole. 2. If the compound of item 1 of the patent application scope, where Q is enthalpy &gt;r-o (詩先閲tr背面之注意事項再項寫本頁) 經濟邾中央標竿局to:工;fl費合作让印s — C0‘0R8 ,或CN, RL是璟丙基,甲基環丙基,異丙基,甲氣基甲基或三氟曱基,R8是乙基,異丙基或叔 一丁基,和其藥學上可接受的薛加成鹽或水合物。 3 .如申諳專利範圍第1或2項之化合物,其中R 2 和R A分別是氫,甲基,乙基,羥乙基,甲氯基乙基,2 ,2 —二甲氣基乙基,二曱基胺基乙基,環丙基甲基,乙 氧基羰基甲基,N-曱基谛啶基或(1, 3_二噁烷一2 •基)一甲基,或R2和R3 —起和氮原子形成暍啉基, 硫代嗎啉,氣一或二氯硫代嗎啉,K咯烷基,呢啶基或噻 唑烷基,這些環条绽中的每一茴1擇性技罕基,丙基,苯 基,羥基,羥甲基,羥乙基或甲氧基甲基所取代,及其藥 學上可接受的酸加成g或水合物。 4.如申請專利範圍第1項之化合物,其中R4 , R 5 , R 6 和 R 7 分別是氫,C 1 , B r , F , 0 C Η 3 . C Ν ,三氟化甲基或甲基,和其藥學上#可接受的酸加成13 ·&quot;.· (CNS) r 4 ,·:!0 X :r-~ ) i: A7 B7 C7 D7 六、申請專利範圍 或水合物。 5.如申請專利範圍第1項之化合物,其是還自: 3 - (3 —璟丙基一 1, 2, 4 —氣二氮茂一 5 —基)一 7 —氪一 5 —嗎啉一咪唑〔1, 5 — a〕喹唑咐, 3 - (3 —環丙基—1, 2,4 一氧二氮茂一 5 -基)— 5 —嗎啉一6 —三氟化甲基一眯唑〔1, 5_a〕喹唑啉 » 3 - (3 -璟丙基-1,2, 4 - 氯二氮 S - 5 - 基)- 6 —氣一 5 —媽咐一昧睡〔1# 5 — a〕喹唑琳, 3 — (3 —環丙基—1,2,4 —氯二氮 S — 5 —基)— 6 -氟一 5 - (順一 2, 6 —二甲基嗎啉)一眯唑〔1, 5 — a〕嗤睡琳, 3 - ·&lt;3 -環丙基-1, 2, 4 —氣二氮茂一 5 —基)一 6 —氟一5 —硫代嗎咐_眯陛〔1, 5 - a〕喹陛咐, 3 一 (3 —環丙基一1, 2, 4 —氧二氮茂一 ·5 -基)一 / 6 —氟一 5 — (4 一甲基—1—對二氮己璟基)一眯唑〔 1, 5 - a〕喹唑咐, 3 — (5 —環丙基一 1, 2, 4 —氧二氛茂一 3 —基)一 5 — (反—2, 5 —二甲基嗎啉)-6 —氣-咪唑〔1, 5 - a〕喹唑咐 3— (5 —環丙基一 1, 2, 4 —氧二気茂一3 -基)一 5 —(順一2, 5 — 二甲基嗎咐)一 6—® —眯 _〔1, 5 — a〕喹唑咐, (请先閏讀背面之注意事項再項寫本頁) ·-* -驾· 經濟邡中央標準局w:工消費合作社印*&gt; ro (Poetry first read the notes on the back of tr and then write this page) Economical Central Bureau of Standards to: work; fl fee cooperation to make prints — C0'0R8, or CN, RL is Jingpropyl, methyl Cyclopropyl, isopropyl, methylmethyl or trifluoromethyl, R8 is ethyl, isopropyl or tert-butyl, and its pharmaceutically acceptable Xue addition salts or hydrates. 3. Compounds as claimed in item 1 or 2 of the patent scope, where R 2 and RA are hydrogen, methyl, ethyl, hydroxyethyl, methylchloroethyl, 2,2-dimethylaminoethyl , Dimethylaminoethyl, cyclopropylmethyl, ethoxycarbonylmethyl, N-methylpyridinyl or (1, 3_dioxane-2-yl) -methyl, or R2 and R3-together with the nitrogen atom to form chrysoline, thiomorpholine, gas mono- or dichlorothiomorpholine, K-pyrrolidinyl, pyridinyl or thiazolidinyl, each of these ring strips is selected Propyl, propyl, phenyl, hydroxy, hydroxymethyl, hydroxyethyl or methoxymethyl substituted, and its pharmaceutically acceptable acid addition g or hydrate. 4. The compound as claimed in item 1 of the patent scope, wherein R4, R5, R6 and R7 are hydrogen, C1, Br, F, 0 C Η 3. C Ν, trifluoride methyl or methyl (CNS) r 4, ·:! 0 X: r- ~) i: A7 B7 C7 D7 VI. Patent scope or hydrate. 5. If the compound of the first item in the scope of patent application, it is also from: 3-(3-propyl propyl 1, 2, 4-gas diazenium-5-yl)-7-krypton-5-morpholine one Imidazole [1, 5-a] quinazol, 3-(3-cyclopropyl-1, 2, 4, oxydiazepine-5-yl)-5-morpholine 6-trifluoromethyl squint Azole [1, 5_a] quinazoline »3-(3-Jing propyl 1,2, 4-chlorodiazepine S-5-yl)-6-Qi Yi 5-Mom told a sleep [1 # 5 — A] Quinazoline, 3 — (3-cyclopropyl—1,2,4-chlorodiazepine S — 5 —yl) — 6-fluoro-5- (cis-2,6-dimethylmorpholine) Azole [1, 5-a] Ozarin, 3-· &lt; 3-Cyclopropyl-1, 2, 4 -gas diazenium-5-yl) -6-fluoro-5-thiothio _ 眯 陛 〔1, 5-a〕 Quan, 3 1- (3-cyclopropyl-1, 2, 4-oxodiazepine-5-yl) mono-6-fluoro-5- (4-monomethyl Yl-1-p-diazepine (yl) -pyrazole [1, 5-a] quinazol, 3-(5-cyclopropyl 1, 2, 4-oxydichloromethane-3-yl)-5 — (Anti-2, 5 — two Ylmorpholine) -6-gas-imidazole [1,5-a] quinazol 3- (5-cyclopropyl-1,2,4-oxodiohydra-3-yl) -5- (cis-2, 5 — dimethyl?) 6—® — 眯 _ [1, 5 — a] Quinazol, (please read the notes on the back first and then write this page) ·-* -Driver · Economic Central Government Bureau of Standards w: printed by industrial and consumer cooperatives * A7 B7 C7 D7 e濟部中央揉竿局两工&quot;&quot;合忭让印&quot; 六、申請專利範圍 3 一 ( 3 — 環 丙 基 一 5 一 m 唑 ) 一 6 — 氟 一 5 — 嗎 琳 咪 唑 C 1 9 5 — a ] 喹 唑 啉 9 3 一 ( 3 一 環 丙 基 — 1 » 2 9 4 — 氣 二 氮 技 一 5 — 基 ) — 5 一 ( N — ( 1 &gt; 3 — 二 噁 院 — 2 — 基 ) 甲 基 — N — 甲 基 胺 基 ) — 6 — 氩 一 眯 唑 C 1 » 5 一 a 3 喹 唑 啉 » 3 一 ( 5 — 環 丙 基 — 1 I 2 » 4 — 氣 二 氮 茂 — 3 — 基 ) — 5 — ( 2 1 6 — 二 甲 基 / 1 — 顿 啶 基 ) — 6 — 氟 — 眯 唑 C 1 &gt; 5 — a 3 m 唑 啉 0 6 • 一 種 用 於 治 療 中 m 神 经 統 疾 病 的 m 學 组 成 物 I 包 含 — 定 量 之 可 減 輕 該 疾 病 之 如 申 請 專 利 範 圍 第 1 5 項 之 化 合 物 或 其 藥 學 上 可 接 受 之 酸 加 成 塩 及 一 藥 學 上 可 接 受 的 戟 趕 或 m 釋 劑 〇 .7 • 如 申 13 專 利 範 圍 第 6 -- 項 之 化 合 物 « 其 是 以 P 服 劑 量 的 型 式 存 在 t 包 含 0 • 1 — 1 〇 〇 m g 的 活 性 化 合 物 〇 8 • 如 申 請 專 利 範 圍 第 1 項 之 化 合 物 梦 其 是 m 於 製 備 — 種 甩 以 治 療 m 於 中 植 神 绖 条 统 疾 病 的 學 組 成 物 〇 Q • 如 請 利 範 圍 第 g 之 化 —八_ &gt; 其 Ψ 該 疾 病 曰 痙 m t 焦 盧 或 失 眠 〇 1 0 一 種 製 備 如 請 專 利 &gt;«w 圍 第 1 至 5 項 中 任 — 項 之化合物的方法,其特徵為a )反應一式I I化合物和式I I I化合物, (請先閲讀背面之注意事項再項寫本頁) 本(CNS) γ (.二'' X :厂二、U ) ό Α7 Β7 C7 D7 申請專利範圍 EA7 B7 C7 D7 e Ministry of Economic Affairs Central Kneading Rod Bureau "two" &";" and "combination permit printing" "Six, apply for patent scope 3 one (3-cyclopropyl one 5 one m azole) one 6-fluorine one 5- Linimidazole C 1 9 5 — a] Quinazoline 9 3 mono (3 -cyclopropyl — 1 »2 9 4 — gas diazoxide mono 5 — yl) — 5 mono (N — (1 &gt; 3 — diox -2-yl) methyl-N-methylamino)-6-argon quinazoline C 1 »5-a 3 quinazoline» 3 one (5 — cyclopropyl — 1 I 2 »4 — gas Diazepine — 3 — yl) — 5 — (2 1 6 — dimethyl / 1 — pentidinyl) — 6 — fluoro — mebendazole C 1 &gt; 5 — a 3 m oxazoline 0 6 • one for The m-composition I for the treatment of m-neuropathy includes-quantitatively the compound as claimed in item 15 of the patent application or its pharmaceutically acceptable acid addition compound and a pharmaceutically acceptable halberd Rush or m release agent 〇 .7 • For example, the compound in the patent scope item 6-item «which is in the form of a p-dosage t t containing 0 • 1-1 〇〇mg active compound 〇8 • as the patent application item 1 compound Meng Qi is m in preparation-a scientific composition that is thrown to treat m in the planting of the sacred ridge system disease. QQ: If you want to benefit from the scope of the gth-eight_ &gt; its Ψ the disease is spasm mt Jiao Lu or Insomnia 〇1 0 A method for preparing a compound as claimed in any one of items 1 to 5 in Patent «w Surrounding, characterized by a) reacting a compound of formula II and a compound of formula III, (please read the notes on the back first Write this page again) This (CNS) γ (.2 '' X: Factory II, U) ό Α7 Β7 C7 D7 Patent application scope E _(π) (請先閲讀背面之注意事項再項窵本頁) 其中R2 , R3 , R4 , RS , RS@R7是如申請專利 範圍第1項所定義者,其中Y是一離去基, C Ν - C Η 2 - Q (III) 其中Q是如申請專利範圍第1項所定義者,以形成一式I 化合物,或b)反應一具有通式IV化合物之反腠衍生物 和一具有通式V之化合物: -窣- •^·_ (π) (Please read the precautions on the back before entering this page) where R2, R3, R4, RS, RS @ R7 are as defined in item 1 of the patent application scope, where Y is a leaving group, C Ν-C Η 2-Q (III) where Q is as defined in item 1 of the patent application, to form a compound of formula I, or b) reacting a compound with a general formula IV and a derivative The compound of formula V:-窣-• ^ · CCOH V ) .综· fe濟部中央揉準局w:工消&quot;合作社印s 其中R2 , R 3 , R4 , Rs , R6和R7是如申請專利 範圍第1項所定義者, Rl - C ( = NOH) NHz (V) 其中R1是如申II專利範圍第1項所定義者,以形成一式 -6 - 本 尺中?; (CNS)甲 4 (210 X 297 二、9 ) A7 B7 C7 D7 六、申請專利範圍 I化合物,其中Q是CCOH V). Comprehensive · Fe Ministry of Economics Central Bureau of Quotations w: Cooperatives & Cooperatives Cooperatives where R2, R3, R4, Rs, R6 and R7 are as defined in item 1 of the patent application scope, Rl-C (= NOH) NHz (V) where R1 is as defined in item 1 of the scope of the patent application II to form a formula -6-in this ruler? ; (CNS) A 4 (210 X 297 II, 9) A7 B7 C7 D7 VI. Patent application scope I compounds, where Q is 其中R1是如申請專利範圍第1項所定義者,或 c)反應一式VI化合物和一脱水劑, (請先閏讀背面之注意箏項再塡寫本頁) 7 n XTWhere R1 is as defined in item 1 of the patent application scope, or c) reacts a compound of formula VI and a dehydrating agent, (please read the note on the back of the leap before writing this page) 7 n XT 其中-R2 , R3 , R4 , Rs , Rs和R7是如申諳專利 範圍第1項所定義者,以形成一式I化合物,其中R2 , R 3 ·, R 4 , Rs , Rs和R7是如申請專利範圍所定義Where -R2, R3, R4, Rs, Rs and R7 are as defined in Item 1 of the patent scope to form a compound of formula I, where R2, R3, R4, Rs, Rs and R7 are as applied Defined by patent scope •轄. 本汰 尺Λϋ 刃中(CNS)甲 4 (210 X 二、公)• Jurisdiction. This ruler Λϋ Blade Middle (CNS) A 4 (210 X II, male) 六、申請專利範圍 . · 其中R 2 , R 3 , R 4 , R 5 , R 6和R 7是如申請專利 範圍第1項所定義者,以形成一式VIII化合物6. Scope of patent application. · Among them, R 2, R 3, R 4, R 5, R 6 and R 7 are as defined in item 1 of the patent application scope to form a compound of formula VIII 其中R2 , R 3 , R 4 , R s , Rs和R7是如申請專利 範圍第1項所定義者,且反應此式VI I Γ化合物和R1 —C〇OE t或和(R1 C0) 2 0,其中R1是如上述 所定義者,以形成式I化合物,其中Q是 (請先閲讀背面之注意事項再堉寫本頁) N-0Where R2, R3, R4, Rs, Rs and R7 are as defined in item 1 of the patent application scope, and reflect this formula VI I Γ compound and R1-C〇OE t or and (R1 C0) 2 0 , Where R1 is as defined above to form a compound of formula I, where Q is (please read the precautions on the back before writing this page) N-0 其中R1是如申請專利範圍第1項所定義/者,或 e )水解式I化合物以形成式I X化合物 綬濟部中央揉準局*:工&quot;&quot;合作社印*Where R1 is as defined in item 1 of the patent application scope, or e) hydrolyze the compound of formula I to form a compound of formula I X Central Ministry of Economic Development, Ministry of Economic Affairs *: Gong &quot; &quot; Cooperative Society * X 本义苡用中?:汽孕(CNS)甲4(210 X y公) •. Α7 Β7 C7 D7 六、申請專利範圍 其中Q , R 4 , R 5 , R 6和R 7是如申'ϋ專利範'圍第1 項所定義者,且反應式IX化合物和POC 13以形成式 X化合物X The original meaning is in use? : Automobile pregnancy (CNS) A 4 (210 X y male) • Α7 Β7 C7 D7 Six, the scope of patent application, Q, R 4, R 5, R 6 and R 7 is the first place in the application for “ϋ patent range” As defined in the item, and the compound of formula IX and POC 13 are reacted to form the compound of formula X X 其和式X I化合物反應 N H R 2 R 3 (XI) 其中.R2和R3具有如申諳專利範圍第1項之定義者,以 形成式I化合物。 (請先閲讀背面之注意事項再塡寫本頁) 本认 甲中 家 (CNS)甲 4 (21C X )X It reacts with the compound of formula X I N H R 2 R 3 (XI) where .R2 and R3 have the definition as defined in item 1 of the patent scope to form the compound of formula I. (Please read the precautions on the back before writing this page) This Approval A China Home (CNS) A 4 (21C X)
TW081110173A 1991-12-20 1992-12-18 TW211568B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK912042A DK204291D0 (en) 1991-12-20 1991-12-20 HETEROCYCLIC RELATIONSHIPS OF THEIR PREPARATION AND USE

Publications (1)

Publication Number Publication Date
TW211568B true TW211568B (en) 1993-08-21

Family

ID=8109668

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081110173A TW211568B (en) 1991-12-20 1992-12-18

Country Status (12)

Country Link
EP (1) EP0619820A1 (en)
JP (1) JPH07502278A (en)
AU (1) AU673814B2 (en)
CA (1) CA2125854A1 (en)
DK (1) DK204291D0 (en)
FI (1) FI942963A (en)
IL (1) IL104099A (en)
NO (1) NO942301L (en)
NZ (1) NZ246558A (en)
TW (1) TW211568B (en)
WO (1) WO1993013103A1 (en)
ZA (1) ZA929770B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK151890D0 (en) * 1990-06-22 1990-06-22 Ferrosan As HETEROCYCLIC RELATIONSHIPS OF THEIR PREPARATION AND USE
CN1052724C (en) * 1996-07-01 2000-05-24 瑞安大药厂股份有限公司 Optical active 2, 3-dihydro-imidazole and [1, 2-c] quinazoline derivative, preparation method and use thereof
KR100864364B1 (en) 2005-12-13 2008-10-17 주식회사 엘지화학 Novel imidazoquinazoline derivative, process for preparing the same, and organic electronic device using the same
WO2008106128A2 (en) 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
AR069207A1 (en) 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc CYCLIC UREAS AS INHIBITORS OF THE 11 BETA - HIDROXI-ESTEROIDE DESHIDROGENASA 1
JP5490014B2 (en) 2007-12-11 2014-05-14 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 11β-hydroxysteroid dehydrogenase type 1 cyclic urea inhibitor
TW201016691A (en) 2008-07-25 2010-05-01 Boehringer Ingelheim Int Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
NZ590495A (en) 2008-07-25 2012-10-26 Vitae Pharmaceuticals Inc Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8637505B2 (en) 2009-02-04 2014-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8680093B2 (en) 2009-04-30 2014-03-25 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
US8933072B2 (en) 2010-06-16 2015-01-13 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2011161128A1 (en) 2010-06-25 2011-12-29 Boehringer Ingelheim International Gmbh Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
EA201300522A1 (en) 2010-11-02 2013-11-29 Бёрингер Ингельхайм Интернациональ Гмбх PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS
WO2022078480A1 (en) * 2020-10-16 2022-04-21 上海迪诺医药科技有限公司 Triheterocyclic derivative, and pharmaceutical composition and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0274009B1 (en) * 1985-10-17 1992-09-09 Novo Nordisk A/S Oxadiazolylacetonitriles, their preparation and use
DK155524C (en) * 1987-03-18 1989-09-11 Ferrosan As CONDENSED IMIDAZOLD DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE
DK443589D0 (en) * 1989-09-08 1989-09-08 Ferrosan As HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE
DK151890D0 (en) * 1990-06-22 1990-06-22 Ferrosan As HETEROCYCLIC RELATIONSHIPS OF THEIR PREPARATION AND USE

Also Published As

Publication number Publication date
NO942301D0 (en) 1994-06-17
NZ246558A (en) 1995-07-26
IL104099A0 (en) 1993-05-13
IL104099A (en) 1996-07-23
FI942963A0 (en) 1994-06-20
FI942963A (en) 1994-06-20
EP0619820A1 (en) 1994-10-19
AU673814B2 (en) 1996-11-28
CA2125854A1 (en) 1993-07-08
WO1993013103A1 (en) 1993-07-08
JPH07502278A (en) 1995-03-09
AU3344893A (en) 1993-07-28
DK204291D0 (en) 1991-12-20
ZA929770B (en) 1994-06-17
NO942301L (en) 1994-08-19

Similar Documents

Publication Publication Date Title
TW211568B (en)
JP4074509B2 (en) Methods and intermediates for producing anticancer compounds
ES2367666T3 (en) DERIVATIVES OF [4,5 &#39;] BIPIRIMIDINIL-6,4&#39;-DIAMINE AS PROTEIN QUINASA INHIBITORS.
JP6976947B2 (en) Vipyrazolyl derivative useful for the treatment of autoimmune diseases
TW209862B (en)
CN103403003B (en) Bridging piperidine derivative
CA2673003A1 (en) Quinazolines for pdk1 inhibition
CA2045359C (en) 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
EA005407B1 (en) Benzoimidazole derivatives useful as antiproliferative agent
CN109890820A (en) Amino-pyrazol as neurotrophic factor tyrosine kinase receptor inhibitor and pyrimidine compound
CN103889987A (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
CA2727251A1 (en) 2 -arylaminoquinazolines for treating proliferative diseases
EA017442B1 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
BR112015019627B1 (en) COMPOUNDS OF HETEROCYCLIC AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH COMPOUNDS AND USES THEREOF TO TREAT ULCERATIVE COLITIS, CROHN&#39;S DISEASE, RHEUMATOID ARTHRITIS, PSORIASIS, SPONDYLOARTHRITIS, SYSTEMIC-ON-APPEARING JUVENILE IDIOPATHIC ARTHRITIS (SOJIA), OSTEOARTHRITIS AND MULTIPLE Sclerosis
CN104341425B (en) Deuterated acetylene-derivative, its pharmaceutical composition and application
BR112015007731B1 (en) Compound, pharmaceutical composition comprising it and use thereof
DE3883033T2 (en) Heterocyclic compounds and their production and application.
US8957077B2 (en) Pyrazolopyrimidine PDE 10 inhibitors
WO2012044090A2 (en) Novel aminoquinazoline compound having a protein-kinase inhibiting action
CN111410659B (en) PDE9 inhibitors and uses thereof
CN111406054A (en) 1, 2, 4-oxadiazole derivatives as inhibitors of histone deacetylase 6
JP2002510695A (en) Thiazolo [4,5-d] pyrimidines and pyridines as corticotropin releasing factor (CRF) antagonists
WO2021228248A1 (en) Fused aza-heterocyclic amide compound and use thereof
TW542833B (en) Benzoxazinone dopamine D4 receptor antagonists
JP2017122103A (en) Pyrazole carboxamide derivatives as taar regulator for use in treatment of several disorders such as depression, diabetes and parkinson&#39;s disease